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Abstract
Exercise-based cardiac rehabilitation for chronic heart
failure: the EXTRAMATCH II individual participant data
meta-analysis
Rod S Taylor,1,2* Sarah Walker,1 Oriana Ciani,1,3 Fiona Warren,1
Neil A Smart,4 Massimo Piepoli5 and Constantinos H Davos6
1Institute of Health Research, University of Exeter Medical School, Exeter, UK
2Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK
3Centre for Research on Health and Social Care Management, Bocconi University, Milan, Italy
4School of Science and Technology, University of New England, Armidale, NSW, Australia
5Heart Failure Unit, Cardiology, Guglielmo da Saliceto Hospital, Piacenza, Italy
6Biomedical Research Foundation, Academy of Athens, Athens, Greece
*Corresponding author r.taylor@exeter.ac.uk
Background: Current national and international guidelines on the management of heart failure (HF)
recommend exercise-based cardiac rehabilitation (ExCR), but do not differentiate this recommendation
according to patient subgroups.
Objectives: (1) To obtain definitive estimates of the impact of ExCR interventions compared with no
exercise intervention (control) on mortality, hospitalisation, exercise capacity and health-related quality of
life (HRQoL) in HF patients; (2) to determine the differential (subgroup) effects of ExCR in HF patients
according to their age, sex, left ventricular ejection fraction, HF aetiology, New York Heart Association class
and baseline exercise capacity; and (3) to assess whether or not the change in exercise capacity mediates
for the impact of the ExCR on final outcomes (mortality, hospitalisation and HRQoL), and determine if this is
an acceptable surrogate end point.
Design: This was an individual participant data (IPD) meta-analysis.
Setting: An international literature review.
Participants: HF patients in randomised controlled trials (RCTs) of ExCR.
Interventions: ExCR for at least 3 weeks compared with a no-exercise control, with 6 months’ follow-up.
Main outcome measures: All-cause and HF-specific mortality, all-cause and HF-specific hospitalisation,
exercise capacity and HRQoL.
Data sources: IPD from eligible RCTs.
Review methods: RCTs from the Exercise Training Meta-Analysis of Trials for Chronic Heart Failure
(ExTraMATCH/ExTraMATCH II) IPD meta-analysis and a 2014 Cochrane systematic review of ExCR
(Taylor RS, Sagar VA, Davies EJ, Briscoe S, Coats AJ, Dalal H, et al. Exercise-based rehabilitation for heart
failure. Cochrane Database Syst Rev 2014;4:CD003331).
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Results: Out of the 23 eligible RCTs (4398 patients), 19 RCTs (3990 patients) contributed data to this IPD
meta-analysis. There was a wide variation in exercise programme prescriptions across included studies.
Compared with control, there was no statistically significant difference in pooled time-to-event estimates in
favour of ExCR, although confidence intervals (CIs) were wide: all-cause mortality had a hazard ratio (HR)
of 0.83 (95% CI 0.67 to 1.04); HF-related mortality had a HR of 0.84 (95% CI 0.49 to 1.46); all-cause
hospitalisation had a HR of 0.90 (95% CI 0.76 to 1.06); and HF-related hospitalisation had a HR of 0.98
(95% CI 0.72 to 1.35). There was a statistically significant difference in favour of ExCR for exercise capacity
and HRQoL. Compared with the control, improvements were seen in the 6-minute walk test (6MWT)
(mean 21.0 m, 95% CI 1.57 to 40.4 m) and Minnesota Living with Heart Failure Questionnaire score
(mean –5.94, 95% CI –1.0 to –10.9; lower scores indicate improved HRQoL) at 12 months’ follow-up.
No strong evidence for differential intervention effects across patient characteristics was found for any
outcomes. Moderate to good levels of correlation (R2trial > 50% and p > 0.50) between peak oxygen uptake
(VO2peak) or the 6MWT with mortality and HRQoL were seen. The estimated surrogate threshold effect
was an increase of 1.6 to 4.6 ml/kg/minute for VO2peak.
Limitations: There was a lack of consistency in how included RCTs defined and collected the outcomes:
it was not possible to obtain IPD from all includable trials for all outcomes and patient-level data on
exercise adherence was not sought.
Conclusions: In comparison with the no-exercise control, participation in ExCR improved the exercise and
HRQoL in HF patients, but appeared to have no effect on their mortality or hospitalisation. No strong evidence
was found of differential intervention effects of ExCR across patient characteristics. VO2peak and 6MWT
may be suitable surrogate end points for the treatment effect of ExCR on mortality and HRQoL in HF. Future
studies should aim to achieve a consensus on the definition of outcomes and promote reporting of a core
set of HF data. The research team also seeks to extend current policies to encourage study authors to allow
access to RCT data for the purpose of meta-analysis.
Study registration: This study is registered as PROSPERO CRD42014007170.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
Exercise-based cardiac rehabilitation (ExCR) is currently recommended in both the UK and internationalclinical guidelines for people with heart failure (HF). However, it remains uncertain as to whether or
not the effects of cardiac rehabilitation are consistent across patient subgroups (e.g. men vs. women).
This study sought to review available scientific evidence using individual participant data (IPD) to look at
this issue.
Electronic literature databases were searched for published studies and anonymised IPD from the
researchers who conducted these research studies was sought. It was possible to bring together data from
3900 people with HF.
Although the analyses of these data show that participation in ExCR does not appear to have an impact
on the risk of death or hospitalisation, participation does offer some improvement in the physical fitness
and quality of life of people with HF. It was also found that these benefits were irrespective of a patient’s
age, sex, ethnicity, initial level of physical fitness or disease severity.
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Scientific summary
Background
People with symptomatic heart failure (HF) are living for longer following the onset of their condition,
increasing the importance of effective and accessible services for these patients. Exercise-based cardiac
rehabilitation (ExCR) is recognised as integral to the comprehensive care of HF patients. ExCR is a process
by which patients, in partnership with health professionals, are encouraged and supported to achieve and
maintain optimal physical health. Current national [National Institute for Health and Care Excellence. Chronic
Heart Failure in Adults: Management. Clinical Guideline [CG108]. URL: www.nice.org.uk/guidance/CG108
(accessed 25 June 2018)] and international [Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH,
et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College
of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation
2013;128:e240–327; Working Group on Cardiac Rehabilitation; Exercise Physiology and Working Group on
Heart Failure of the European Society of Cardiology. Recommendations for exercise training in chronic heart
failure patients. Eur Heart J 2001;22:125–35; and McMurray JJ, Adamopoulos S, Anker SD, Auricchio A,
Böhm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart
failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of
the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of
the ESC. Eur Heart J 2012;33:1787–847] guidelines on the management of HF recommend ExCR, but do
not differentiate according to patient subgroups.
Objectives
The Exercise Training Meta-Analysis of Trials for Chronic Heart Failure (ExTraMATCH/ExTraMATCH II)
project aimed to determine which HF patient subgroups benefit most from ExCR using individual
participant data (IPD) meta-analysis.
The project had three objectives:
1. To obtain definitive estimates of the impact of ExCR interventions compared with no exercise
intervention (control) on mortality, hospitalisation, exercise capacity and health-related quality of life
(HRQoL) in HF patients.
2. To determine the differential (subgroup) effects of ExCR in HF patients according to their:
¢ age
¢ sex
¢ left ventricular ejection fraction
¢ HF aetiology
¢ New York Heart Association (NYHA) class
¢ baseline exercise capacity.
3. To assess whether or not the change in patient exercise capacity mediates, and is an acceptable
surrogate end point for, the impact of ExCR on final outcomes of mortality, hospitalisation and HRQoL.
The information gained from the ExTraMATCH II project will inform future UK and international clinical
and policy decision-making on the use of ExCR in HF.
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Methods
This study was conducted and reported in accordance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) IPD statement. Randomised controlled trials were identified from
the original ExTraMATCH IPD meta-analysis [Piepoli MF, Davos C, Francis DP, Coats AJ, ExTraMATCH
Collaborative. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH).
BMJ 2004;328:189] and the 2014 Cochrane systematic review of ExCR for HF (Taylor RS, Sagar VA, Davies EJ,
Briscoe S, Coats AJ, Dalal H, et al. Exercise-based rehabilitation for heart failure. Cochrane Database Syst Rev
2014;4:CD003331). ExTraMATCH and the Cochrane systematic review were based on searches of the
following electronic databases: Cochrane Central Register of Controlled Trials in The Cochrane Library,
EMBASE, MEDLINE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), PsycINFO and the
NHS Centre for Reviews and Dissemination. Conference proceedings and trial registers were also searched.
In keeping with the original ExTraMATCH IPD meta-analysis, trials of exercise training (for at least 3 weeks)
compared with no exercise control with ≥ 6 months’ follow-up were included if they provided IPD on
all-cause or HF-specific mortality, hospitalisation, exercise capacity or HRQoL. The data sets of IPD were
combined into a single data set. One-stage fixed-effect meta-analyses of time-to-event end points were
performed using Cox proportional hazards models, stratified by study. One-stage meta-analyses of
continuous outcomes were performed using hierarchical linear models with adjustments for baseline values
and a random effect on study. Two-stage models using fixed and random effects were also performed.
Interaction terms between ExCR and participant characteristics were used to assess potential differential
effects of ExCR across subgroups. Mediational analyses and meta-analytic regressions, with estimation
of R2 at the trial level, and surrogate threshold effect (STE), were performed to assess the question of
surrogate validity for exercise capacity outcomes of peak oxygen uptake (VO2peak) and the 6-minute walk
test (6MWT).
Results
Of the 23 eligible trials (4398 patients), 19 trials contributed data to the IPD meta-analysis [18 trials
(3912 patients) to the clinical events (mortality and hospitalisation) analysis, 13 trials (3332 patients) to
exercise capacity and HRQoL analysis, and 10 trials (2656 patients) to the exercise capacity mediational/
surrogate end-point analysis].
Characteristics and quality of included trials
Patient characteristics at baseline were well balanced between ExCR and control group patients. The
majority of patients were male (74%), had a mean age of 61 years, had experienced heart failure with
reduced ejection fraction (HFrEF) (mean baseline left ventricular ejection fraction 26.7%), and most
patients were in NYHA functional class II (59%) or III (37%). No included trials recruited patients with HF
with a preserved ejection fraction of > 45%. Trials were conducted in Europe and North America and
were published between 1990 and 2012, and the sample sizes ranged from 50 to 2130 patients. All trials
evaluated an aerobic exercise intervention, which was most commonly delivered in either an exclusively
centre-based setting or a centre-based setting in combination with some home exercise sessions. The dose
of exercise training ranged widely across trials. ExCR was delivered over a period of 12–90 weeks, with
between two and seven sessions per week (median session duration was between 15 and 120 minutes,
including warm-up and cool-down). The intensity of exercise ranged between 50% and 85% VO2peak.
The overall quality of included trials was measured using the Tool for the assEssment of Study qualiTy and
reporting in EXercise (TESTEX), a measure of study quality and reporting. Most studies were judged as
being moderate to good, with a median TESTEX score of 11 (range 9–14) out of a maximum score of 15.
Impact of ExCR on mortality and hospitalisation
Compared with control, there was no statistically significant difference in pooled time-to-event estimates in
favour of ExCR, although confidence intervals (CIs) were wide: all-cause mortality had a hazard ratio (HR)
of 0.83 (95% CI 0.67 to 1.04); HF-related mortality had a HR of 0.84 (95% CI 0.49 to 1.46); all-cause
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hospitalisation had a HR of 0.90 (95% CI 0.76 to 1.06); and HF-related hospitalisation had a HR of 0.98
(95% CI 0.72 to 1.35). No strong evidence for differential intervention effects across patient characteristics
was found.
Impact of ExCR on exercise capacity and health-related quality of life
Compared with the control, there was a statistically significant difference in favour of ExCR for exercise
capacity and HRQoL. For example, at 12 months’ follow-up, improvements were seen in the 6MWT
(mean 21.0 m, 95% CI 1.57 to 40.4 m; p = 0.034, τ2 = 491, I2 = 78%) and the Minnesota Living with
Heart Failure Questionnaire score (mean –5.94, 95% CI –1.0 to –10.9; p = 0.018, τ2 = 77, I2 = 88%); lower
scores indicate improved HRQoL. No strong evidence for differential intervention effects across patient
characteristics was found.
Validation of exercise capacity as a surrogate end point
Moderate to good levels of correlation (R2trial > 50% and p > 0.50) between exercise capacity VO2peak or
6MWT with mortality and HRQoL were seen. Estimated STE was an increase of 1.6 to 4.6 ml/kg/minute for
VO2peak. The results indicate that an increase in VO2peak or an improvement in the 6MWT with ExCR is a
potentially weak mediator of final outcomes.
Discussion
In HFrEF patients, ExCR did not have a statistically significant effect on the risk of mortality and
hospitalisation. However, uncertainty around effect estimates and lack of IPD on exercise adherence
precludes drawing definitive conclusions in these event outcomes. ExCR significantly improves exercise
capacity and HRQoL. No consistent differences were found in ExCR effects across patient subgroups. The
results provide indicative evidence that VO2peak and the 6MWT may be suitable surrogate end points for
the treatment effect of ExCR on final outcomes in HF.
Recommendations for further research
Two central aspects of future data collection are (1) a consensus on the definition, collection and reporting
of core sets of outcome data, concomitant disease/comorbidities and metrics of therapy delivery/uptake;
and (2) the capture of data on patient-level adherence to the amount of exercise training during the ExCR
intervention period. More generally, the research community should continue to implement policies that
encourage primary study authors to make their data sets available, by either depositing in publicly available
repositories or sharing with IPD meta-analysis collaborations when directly requested.
Study registration
This study is registered as PROSPERO CRD42014007170.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Chronic heart failure (HF) is a burgeoning global health challenge that affects 1–2% of adults in theWestern world.1 Although survival after HF diagnosis has improved, prognosis is poor, with 30–40% of
patients dying within a year of diagnosis.2 Patients with HF experience limitations to their exercise capacity
and activities of daily living, reduced health-related quality of life (HRQoL), and an increased risk of hospital
admission rate and all-cause mortality.3,4
The cost of management of HF to the UK NHS was reported to be approximately £1B in 2010.5 According
to the Office for National Statistics, the proportion of the UK population aged ≥ 85 years is projected to
double between 2016 and 2041.6 Owing to increases in both the incidence and the prevalence in HF with
increasing age,7 more demands will be placed on the NHS in this time frame. An increase in the prevalence
of comorbidities in an older population will lead to a greater number of hospitalisations in HF patients.8
With increasing numbers of people living longer with symptomatic HF, the effectiveness and accessibility
of health services for HF patients have never been more important. Exercise-based cardiac rehabilitation
(ExCR) is recognised as being integral to the comprehensive care of HF patients. Cardiac rehabilitation
is a process by which patients, in partnership with health professionals, are encouraged and supported
to achieve and maintain optimal physical health.9 Although exercise training is at the centre of cardiac
rehabilitation, it is accepted that programmes should be comprehensive in nature and include education
and psychological input, focusing on health and lifestyle behaviour change and psychosocial well-being.2–4,9
Previous systematic reviews and meta-analyses have shown exercise-based rehabilitation offers important
health benefits for patients.9–12 Including 33 trials across 4740 HF patients, the 2014 Cochrane review10
shows no difference in pooled all-cause mortality with ExCR [relative risk 0.93, 95% confidence interval
(CI) 0.69 to 1.27]; reduced risk of overall hospitalisation (relative risk 0.75, 95% CI 0.62 to 0.92) and
HF-specific hospitalisation (relative risk 0.61, 95% CI 0.46 to 0.80); and a clinically important improvement
in disease-specific HRQoL on the Minnesota Living with Heart Failure Questionnaire (MLHFQ) (mean
difference –5.8 points, 95% CI –9.2 to –2.4 points). ExCR for HF is therefore recommended by the
National Institute for Health and Care Excellence3 and is a class I recommendation of the joint American
College of Cardiology Foundation and the American Heart Association guidelines and the European
Society of Cardiology guidelines.13–15 These guidelines do not differentiate by patient subgroup but, rather,
recommend cardiac rehabilitation to all HF patients ‘who are able to participate to improve functional
status’.13
Despite this evidence and recommendation by clinical guidelines, the uptake of ExCR for HF remains poor.
Only 16% of UK cardiac rehabilitation centres have a specific rehabilitation programme for HF.16 The
recent ExtraHF Survey reported that only 40% of centres from across 42 European countries implemented
an exercise programme for HF.17 Cardiac rehabilitation centres report a lack of resources as the major
barrier to providing rehabilitation services for HF (i.e. lack of finances, staff and equipment).16,17 A key
potential solution (if supported by evidence) could be targeting exercise-based rehabilitation services to
those HF patients who might experience the greatest benefit in outcomes. Such a differential effect of
treatment across HF patients could improve the overall clinical effectiveness and cost-effectiveness of
rehabilitation for HF and drive improvements in patient uptake of rehabilitation.
Although meta-analyses demonstrate important health benefits with ExCR, there is uncertainty as to
whether or not there are differential effects across HF patient subgroups. Three data sources currently
provide evidence on this issue, but all have weaknesses. First, in 2004, the Exercise Training Meta-Analysis
of Trials for Chronic Heart Failure (ExTraMATCH/ExTraMATCH II) Collaborative Group published an individual
participant data (IPD) meta-analysis based on nine randomised trials of 801 HF patients, which showed
ExCR to reduce all-cause mortality [hazard ratio (HR) 0.65, 95% CI 0.46 to 0.92], and no subgroup [age,
sex, HF aetiology, New York Heart Association (NYHA) class, ejection fraction or exercise capacity] effects.18
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Given the small number of trials, patients and events (193 deaths), these subgroup analyses are likely to
be underpowered. Furthermore, a number of trials have been published since, including Heart Failure:
A Controlled Trial Investigating Outcomes of exercise Training (HF-ACTION), a large US National Institutes
of Health (NIH)-funded randomised trial (2331 HF patients across 82 centres).19 Second, the original analysis
of HF-ACTION found no interactions between treatment allocation (ExCR or no exercise control) and patient
characteristics (age, sex, HF aetiology, NYHA class, ejection fraction or depression score) for the composite
outcome of mortality or hospital admission.19 Although the largest ExCR trial to date, to our knowledge, the
power of this study to detect small subgroup effects remains limited. Finally, meta-regression analysis in the
2014 Cochrane review found no association between trial-level patient characteristics (age, sex, ejection
fraction) and the impact of ExCR.10 However, such analysis is highly prone to study-level confounding
(ecological fallacy) and should be interpreted with great caution. The methodology of IPD meta-analysis
allows more robust analysis of treatment effects in subgroups and consistent analysis of outcome data
across trials, such as enabling time-to-event data analyses adjusted for baseline covariates.
BACKGROUND
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Chapter 2 Aims and objectives
The ExTraMATCH II project aimed to determine which HF patient subgroups benefit most from ExCRusing IPD meta-analysis.
The project objectives were to:
l obtain definitive estimates of the impact of ExCR interventions compared with no exercise intervention
(control) on all-cause mortality, hospitalisation, HRQoL and exercise capacity in HF patients
l determine the differential (subgroup) effects of exercise-based interventions in HF patients according
to their:
¢ age
¢ sex
¢ left ventricular ejection fraction
¢ HF aetiology
¢ NYHA class
¢ baseline exercise capacity
l assess whether or not the change in patient exercise capacity mediates and acts as a surrogate end
point for the impact of the ExCR on all-cause mortality, all-cause hospitalisation and disease-specific HRQoL.
The information gained from the ExTraMATCH II project will inform future national and international
clinical and policy decision-making on the use of ExCR in HF.
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Chapter 3 Methods
This project was undertaken and reported according to current reporting guidelines for IPDmeta-analyses20–22 and was registered with PROSPERO (CRD42014007170).23 The project management
committees are listed in Appendix 1.
Identification of trials for inclusion
Trials were identified from the ExTraMATCH IPD meta-analysis and the 2014 Cochrane systematic review
of ExCR for HF.10,18 The Cochrane review searched (to January 2013) the following electronic databases:
Cochrane Central Register of Controlled Trials in The Cochrane Library, EMBASE, MEDLINE, Cumulative
Index to Nursing and Allied Health Literature (CINAHL), PsycINFO and the NHS Centre for Reviews and
Dissemination (see Appendix 2 for the search strategy). Conference proceedings were searched on Web of
Science. Trial registers (controlled-trials.com and ClinicalTrials.gov) and reference lists of all eligible trials
and identified systematic reviews were also checked. No language limitations were imposed. Details of the
search strategy used are reported elsewhere23 and are included in Appendix 2.
Trials were included if they met the following criteria.
Study design
Randomised controlled trials (RCTs) with a follow-up period of ≥ 6 months (in accordance with the 2014
Cochrane review10).
Target population
Adult patients, aged ≥ 18 years, with a diagnosis of heart failure with reduced ejection fraction (HFrEF)
or heart failure with preserved ejection fraction (HFpEF), based on an objective assessment of the left
ventricular ejection fraction and on clinical findings.
Setting/context
Patients managed in any setting (i.e. hospital, community facility or patient’s home).
ExCR intervention
An ExCR intervention that included at least an aerobic exercise training component performed by
the lower limbs, lasting a minimum of 3 weeks,24 either alone or as part of a comprehensive cardiac
rehabilitation programme, which may also include health education and/or a psychological intervention.
Comparator
A non-exercise group receiving standard medical care or an attention placebo.
Sample size
A sample size of > 50 patients to ensure that the logistical effort in obtaining, cleaning and organising the
data were commensurate with the contribution of the data set to the analysis.25,26
Identified RCTs meeting the inclusion criteria are shown in Appendix 3. Study selection for the 2014
Cochrane review and ExTraMATCH IPD meta-analysis was performed by the original research teams that
performed these studies.10,18 For the purposes of this project, a single researcher (RST) compared the
included studies from these two previous studies and applied the above inclusion criteria.
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Investigator requests
The principal investigators of eligible studies were invited (collaboration invitation) to participate in this IPD
meta-analysis and share their anonymised trial data. The list of variables that principal investigators were
asked to provide was reported in the study protocol27 (see Appendix 4).
Exclusion of trials from individual participant data analysis
Trials were excluded if:
l authors did not respond to the invitation to provide IPD for the ExTraMATCH II analysis in spite of
repeated contact attempts being made
l authors were unable to provide IPD, because the data had been either lost or destroyed
l patients were included in the trial who may also have appeared in another IPD data set.
Ethics approval
The ethics of obtaining data were carefully considered and advice was sought from NHS Digital in April
2016. The original trials had each obtained ethics/institutional review board committee approval and
obtained individual patient consent. Given the fully anonymised nature of all the trial data sets (i.e. no
inclusion of data, such as patient name or date of birth, that would allow individual patients to be
identified), NHS Digital confirmed that there was no further legal/ethics or contractual requirements for
use of these data for the purpose of this project. A revision of the HF-ACTION19 data was obtained via the
NIH data portal, which required that we obtain a letter of approval from the University of Exeter Medical
School Research Ethics Committee. A letter was received on 13 November 2017.
Data management
Data files were received in a variety of formats depending on the security concerns of the host institutions.
In most cases, data transfer was by e-mail of a password-protected file, with a separate e-mail containing the
password. Each raw data file was saved in its original format on receipt and then converted to a Stata® file
(version 14.2, StataCorp LP, College Station, TX, USA). Data cleaning was carried out in each pseudonymised
data set prior to being combined in a master data set. Within the individual data sets, data for each variable
(at the patient level) was checked for accuracy in range, extreme values, internal consistency, missing values
and consistency with published reports. Data discrepancies or missing information were discussed with trial
investigators and corrected, if appropriate.
All data files were stored on a secure password-protected computer server managed in accordance with
the data management standard operating procedures of the UK Clinical Research Collaboration-registered
Exeter Clinical Trials Unit. Access to data at all stages of cleaning and analysis was restricted to core
members of the research team (OC, RST, FW and SW).
Patient and public involvement
As part of the National Institute for Health Research (NIHR) Programme Grants for Applied Research report
[Rehabilitation EnAblement in CHronic Heart Failure (REACH-HF), reference number RP-PG-1210-12004;
www.journalslibrary.nihr.ac.uk/programmes/pgfar/RP-PG-1210-12004/#/ (accessed 1 January 2019)],
a patient and public involvement (PPI) group was established in 2009, which consisted of eight active
members (five with lived experience of HF and three patient caregivers). The PPI group are familiar with
the ongoing portfolio of Cochrane systematic reviews in cardiac rehabilitation.
This IPD meta-analysis was proposed to the PPI group meeting in Truro on 1 November 2015, in which
views were sought on the proposed research questions. Following receipt of funding from NIHR, the
ExTraMATCH II project was presented to the PPI group at a further meeting (held in March 2017).
Members of the group gave views on how the results could be best presented and disseminated to
patients, caregivers and clinicians to have an impact on clinical practice and patient understanding of HF.
Kevin Paul (PPI group chairperson) was a co-applicant for the REACH-HF study and was also a member
METHODS
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of the REACH-HF Programme Steering Committee. Kevin is a core colleague and valued member of our
team and agreed to act as conduit between the Project Advisory Group for ExTraMATCH II and the
established PPI group. The PPI group was asked to contribute to, and give views on, (1) the ExTraMATCH II
protocol (e.g. whether or not the most appropriate outcomes were prioritised), (2) lay summaries of the
ExTraMATCH II project, (3) the implications for clinical practice and future research and (4) the planned
dissemination strategy.
Kevin commented on the plain English summary of the original application and also offered advice on the
plain English summary of the final report. Based on the INVOLVE guidelines,28 we paid expenses that
included the cost of his time to attend Project Advisory Group meetings, plus travel costs.
Statistical analysis
All analyses were carried out in accordance with the principle of intention to treat (i.e. patients were analysed
according to randomised treatment assignment for which complete data was available at follow-up). When
missing data were noted within an individual trial, contact with the author was attempted and data added if
available. Given the relatively small levels of missing outcome and covariate data within trials, we did not
undertake data imputation. When possible, all one- and two-stage analyses used random-effects models,
as the overall data set is likely to include a high degree of clinical heterogeneity across the individual studies
(differences in population, ExCR intervention and comparator).29 All analyses were undertaken using Stata.
Main outcomes
In accordance with the study research objectives, it was sought, from eligible trials, IPD for the following
outcomes:
l Mortality – incidence and time-to-event data for all deaths (we also sought to obtain data on the cause
of death).
l Hospital admission – incidence, time to event and duration of hospitalisation (we also sought to obtain
data on the cause of the hospitalisation).
l Disease-specific HRQoL (as assessed by the MLHFQ and other validated HRQoL outcomes) – value at
baseline (pre randomisation) and at 6, 12, 24 and > 24 months post randomisation.
l Exercise capacity [as assessed by peak oxygen uptake (VO2peak) and other validated exercise capacity
measures] – as measured at baseline and at 6, 12, 24 and > 24 months post randomisation.
Patient subgroups
We also requested individual patient demographic and clinical data, including age, sex, ejection fraction,
NYHA class, HF aetiology (ischaemic vs. non-ischaemic), race/ethnicity and exercise capacity at baseline.
Details of exercise training prescription (i.e. session frequency, duration, intensity and overall programme
duration) was collected as part of the 2014 Cochrane review.10
Statistical analysis plans
A detailed statistical analysis plan was produced for each of the three analyses described below:
1. the impact of ExCR on mortality and hospitalisation outcomes
2. the impact of ExCR on HRQoL and exercise capacity outcomes
3. the validation of exercise capacity as a surrogate outcome.
Descriptive statistics
For each analysis, patient-level characteristics were compared for those patients in the ExCR and control
groups of the included studies. Descriptives of trial-level characteristics by group are also reported.
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Assessment of study quality and risk of bias
We checked for potential small-study bias by visually assessing funnel plot asymmetry and using Egger’s
test.30 Study quality and risk of bias was assessed using the Tool for the assEssment of Study qualiTy and
reporting in EXercise (TESTEX).31 Statistical heterogeneity was assessed using the I2-statistic.29
Impact of ExCR on mortality and hospitalisation
Inclusion of trials
Trials were included in the mortality and hospitalisation analyses if IPD was provided for the one or more
of the outcomes of interest detailed below.
Outcomes of interest
The final patient-relevant outcomes of interest in this study were time to event to:
l all-cause mortality
l HF-related mortality
l all-cause hospital admission
l HF-related hospital admission.
Owing to the inconsistency of reporting in IPD sets, we were able to consider only time-to-event outcomes
and not incidence or duration of events. Insufficient data were made available to allow analyses on
‘sudden death’ to be carried out.
Each of the outcomes described above was analysed separately. Each trial contributed to between one and
four analyses.
Primary analysis
In the primary analysis, a two-stage IPD meta-analysis approach was taken. A Cox regression model was
performed on the data from each trial individually and the resulting HRs used in a random-effects meta-
analysis. For the meta-analysis of treatment–covariate interactions, the same approach was used, with a
Cox regression model applied to the data from each trial and the resulting HR for the interaction effect
used to inform the meta-analysis. A random-effects model was used to account for the high degree of
clinical heterogeneity across the individual studies due to differences in population, ExCR intervention and
comparator.29 An overall estimate of the effect of ExCR for each outcome, both by trial and as a pooled
estimate, was presented as a HR and 95% CI. Additionally, the and I2 and τ2 statistics were reported
alongside the associated p-value for the results of the main analyses.29,32 The Cochrane handbook advises
that using specific threshold values for the interpretation of the I2-statistic can be misleading.33
Secondary analysis
The secondary analysis used a one-stage IPD meta-analysis Cox regression model, stratified by trial.
Stratification allowed the baseline hazard to vary between studies, rather than forcing the hazard in
individual studies to be proportionate to each other.34 No distributional assumptions about this baseline
hazard were made. Owing to failure of convergence in the one-stage random-effect models, probably
due to the low level of heterogeneity between studies, a fixed-effect approach was used.
The within-trials interaction term used here identifies any patient characteristics that influence the
effectiveness of ExCR on an individual level, necessary for making inferences for stratified medicine, as
recommended by Riley et al.35 The within-trial interaction effect is fixed across trials. Continuous covariates
were centred on the mean value within each trial; binary covariates were centred on the proportion within
each trial.
METHODS
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Sensitivity analyses
To test the robustness of the primary and secondary analyses, we undertook a number of prespecified
sensitivity analyses: we excluded the largest trial (HF-ACTION19); truncated outcomes at 1, 2 and 5 years’
follow-up; and included trial-level outcome data for studies that could not provide IPD.26
Impact of ExCR on health-related quality of life and exercise capacity
Inclusion of trials
Trials were included in the HRQoL and exercise capacity analyses if IPD was provided for the one or more
of the outcomes of interest detailed below.
Outcomes of interest
The final patient-relevant outcomes of interest in this study were:
l HRQoL measured using the MLHFQ score
l HRQoL measured through any validated scale
l exercise capacity measured using VO2peak (ml/kg/minute)
l exercise capacity measured using the 6-minute walk test (6MWT) (m)
l exercise capacity measured using a standardised exercise capacity score calculated from any of the four
validated exercise capacity measures [i.e. VO2peak, 6MWT, incremental shuttle walk test (ISWT) and
workload on cycle ergometer].
Health-related quality of life: scales of measurement
Health-related quality of life measured using one of the following three validated measures was included
in this analysis:
1. the MLHFQ36
2. the Kansas City Cardiomyopathy Questionnaire37
3. the Guyatt et al.38 Chronic Heart Failure Questionnaire scale.
The first HRQoL analysis was carried out for trials providing the MLHFQ data; the second analysis used a
standardised score calculated from any of the three measures above.
Exercise capacity: scales of measurement
Exercise capacity measured using one of four validated measures was included in this analysis:
1. VO2peak (ml/kg/minute)
2. distance (m) walked on the 6MWT
3. distance (m) walked in an ISWT
4. workload on cycle ergometer (watts).
Exercise capacity analysis was carried out for:
l trials providing VO2peak
l trials providing the 6MWT
l a standardised exercise capacity score, calculated from any of the validated exercise capacity measures
listed above.
One study, HF-ACTION,19 provided data on both VO2peak and the 6MWT, and was included in all
analyses, with the VO2peak measure taking precedence for the standardised exercise capacity analysis.
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Primary analysis
The primary analyses included one- and two-stage IPD meta-analyses carried out at 6 and 12 months.
At each time point, we used the observation closest to and prior to the time point. All one-stage IPD models
used a hierarchical random-effects regression model, adjusted for the baseline value of the outcome measure.
All two-stage models used random treatment effects. We performed a series of models to estimate the overall
treatment effect and to investigate potential interactions between ExCR and predefined patient subgroups
(i.e. age, sex, left ventricular ejection fraction, HF aetiology, NYHA class and baseline exercise capacity23,27).
Each model investigated one interaction effect only. The I2 and τ2 statistics were reported alongside the
associated p-value for the results of the main analyses.29,32
Secondary analysis
The secondary analyses used a random-effects hierarchical model for repeated measures at multiple time
points. These models utilised HRQoL and exercise capacity outcome data at all available time points.
Adjustments for baseline values of the outcome measure were made; no other covariates were included in
the model. This model included a time-by-treatment interaction term.
Sensitivity analyses
To test the robustness of the primary analyses, prespecified sensitivity analyses were carried out:
l the primary analysis was repeated after exclusion of the largest trial (HF-ACTION19)
l data was added from studies that did not provide IPD.
Surrogate analyses
Inclusion of trials
All studies in the ExTraMATCH II meta-analysis were eligible for inclusion in the surrogate analyses,
dependent on the availability of data on exercise capacity and final patient-relevant outcomes, as explained
below.
Outcomes of interest
The final patient-relevant outcomes of interest in this validation study were:
l HRQoL measured by MLHFQ score
l HRQoL measured through any validated scale
l time to all-cause mortality
l time to all-cause hospital admission.
For this study, three approaches to exercise capacity definition were used:
1. direct assessed VO2peak
2. 6MWT
3. direct and indirect VO2peak (conversion from the 6MWT and the ISWT; no conversion was possible for
watts as it is dependent on the body weight of individual patients).
Distances recorded as either 6MWT or ISWT at baseline were converted to VO2peak using previously
reported methods.39–43 Details can be found in Appendix 5.
Follow-up time considerations
The following outcome follow-up times were considered: ≤ 6 months for exercise capacity outcomes,
≤ 12 months for HRQoL outcomes and all available follow-up time for mortality and hospitalisation.
This approach was consistent with the assumption of temporal antecedence for a causal relationship
between the surrogate end point and the final outcomes.
METHODS
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Mediation analysis
Mediation is known as the phenomenon whereby a cause affects an intermediate variable (also called
mediator), and the change in the intermediate variable goes on to affect the outcome.44,45 The effect of the
cause on the outcome that operates through the intermediate of interest is sometimes referred to as an
indirect or mediated effect. Mediation analysis usually refers to the set of techniques by which a researcher
assesses the relative magnitude of these direct and indirect effects. The product method specification of
this approach was used to determine whether or not a change in VO2peak (ΔVO2peak) or a change in the
6MWT result (Δ6MWT) mediate the relationship between treatment assignment (i.e. ExCR vs. no ExCR),
and each of the final outcomes of interest. Linear or Cox regression analyses were conducted to evaluate
the following four hypotheses:
1. Treatment assignment (i.e. ExCR vs. control) has a significant effect on ΔVO2peak or Δ6MWT from
baseline to 6 months’ follow-up.
2. ΔVO2peak or Δ6MWT have a significant effect on ΔMLHFQ or ΔHRQoL, or on the hazards of developing
a clinical event.
3. Treatment assignment (i.e. ExCR vs. control) has a significant effect on ΔMLHFQ or ΔHRQoL, or on the
hazards of developing a clinical event.
4. The effect of treatment assignment (i.e. ExCR vs. control) on ΔMLHFQ or ΔHRQoL, or on the hazards of
developing a clinical event, is attenuated when ΔVO2peak or Δ6MWT is added to the model.
All regression models took into account the clustering within trials to allow for study-level differences in
treatment effect and unstructured covariance between random intercept and random slope. Regression models
were adjusted for baseline of either exercise capacity values or baseline HRQoL values. No other adjustments
were made, because patients were randomly assigned to intervention or control arm. In testing hypothesis (2),
no adjustment is made for potential confounding variables.
It was assumed necessary to reject the null for at least the first of these hypotheses (i.e. the treatment
assignment is associated with the mediator), to support the validation of ΔVO2peak or Δ6MWT as
mediator end points and proceed further with the estimation of proportion explained or proportion
mediated.
Meta-analytic approach: R2 and surrogate threshold effect
Although mediation analysis considers pathways by which treatment effects may arise, surrogacy
principally concerns whether or not we are able to predict the effect of treatment on the final end point by
using the effect of treatment on the surrogate.
Given the issues described with the proportion explained and indirect effects approaches in identifying
consistent surrogates, the meta-analytic approach may offer the most promise for assessing surrogate
outcomes and for making policy and treatment decisions.46,47 This approach requires multiple studies,
or at least multiple subgroups (e.g. centres within a trial), which we have through the ExTraMATCH II IPD
meta-analysis. As a true and strong association between the treatment effect on the final end point and
the treatment effect on the surrogate is considered to be the hallmark of surrogacy,47 this approach
proceeds as follows. Let ϕj denote the estimate of the effect of treatment on the final outcome in the
jth study, let θj denote the estimate of the effect of treatment on the surrogate outcome in the jth study,
both derived from RCTs. For a good surrogate, a monotonic relationship would exist between ϕj and θj
and, in a regression of ϕj on θj, there would be limited variability around the regression line. If the
relationship between ϕj and θj is approximately linear, a reasonable measure of surrogacy is the R2trial of
the regression of ϕj on θj. Another intuitive measure recommended as a surrogacy metric is the surrogate
threshold effect (STE), which takes into account the variability around the regression line and represents
the intercept of the prediction band of the regression line with the zero effect line on the final outcome.46
For each trial, we estimated study-level treatment effects by conducting linear regression or Cox
proportional hazards regression models. Adjustment was made for baseline exercise capacity or HRQoL
values. Then we conducted linear meta-regressions to relate estimated difference in exercise capacity to
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the estimated effect on change in HRQoL: log(HR) of all-cause mortality or log(HR) of all-cause hospitalisation
events. The square of the inverse standard error was used as a weight to account for uncertainty in the
estimated patient-relevant outcomes effect. We calculated commonly reported indicators of surrogate
validation.48 The correlation coefficient (p-value) and the R2 for the relationship between treatment effect
difference on exercise capacity and each of the final outcomes was estimated individually using weighting
by the inverse of the variance (for the treatment effect on final outcomes). In order to estimate STE,
prediction bands were calculated based on approximate prediction intervals.48,49
METHODS
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Chapter 4 Characteristics and quality of included
studies
Identification of trials for inclusion in the ExTraMATCH II master data set
A total of 23 trials were deemed eligible for the ExTraMATCH II IPD meta-analysis. Data from six trials had
been analysed previously and were available from the ExTraMATCH database.50–55 Fourteen investigators
responded positively and shared their de-identified trial data directly.19,56–68
Exclusion of eligible trials from the ExTraMATCH II master data set
We were unable to include data from three trials (355 patients): for two trials data were no longer available69,70
and the investigators of the other trial could not be contacted.71 After obtaining IPD, a further trial72 was
excluded, as it was determined that it included patient data that overlapped with another trial.62 We therefore
had a total of 19 trials in the ExTraMATCH II study,19,50–67 with a total of 3900 patients. A Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA)22 flow diagram to show inclusion and exclusion of
trials in the ExTraMATCH II study is shown in Figure 1. Further flow diagrams to show inclusion and exclusion
of trials and participants within individual analyses are given in the appropriate results sections.
2014 Cochrane review10
n = 33 trials
(n = 46 publications)
ExTraMATCH II IPD meta-analysis
n = 23 trials met inclusion criteria
(n = 4398 patients)
Excluded trials
(n = 4)
• Data sets destroyed/lost, n = 2
• Trial group uncontactable, n = 1
• Patients duplicated in another
   study, n = 1
RCTs included from
ExTraMATCH18 analysis
n = 4 trials
(n = 4 publications)
Excluded trials
(n = 14)
ExTraMATCH II IPD meta-analysis
n = 19 trials (3900 patients) provided data
• < 50 patients in trial, n = 14
FIGURE 1 The PRISMA flow diagram summarising the selection of studies for the ExTraMATCH II study.
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Characteristics of included patients
Patient characteristics at baseline were well balanced between ExCR and control patients. The majority of
patients were male (74%), with a mean age of 61 years [standard deviation (SD) 13 years]. The mean baseline
left ventricular ejection fraction was 26.7% (SD 8.1%), and most patients were in NYHA functional class II
(59%) or III (37%) (Table 1). No included trials recruited patients with HFpEF (i.e. an ejection fraction of > 45%).
Characteristics of included trials
Trials were from Europe and North America and were published between 1990 and 2012. Sample size
ranged from 50 to 2130 patients. All trials evaluated an aerobic exercise intervention, which was most
commonly delivered in either an exclusively centre-based setting or a centre-based setting in combination
with some home exercise sessions. The dose of exercise training ranged widely across trials. ExCR was
delivered over a period of 12–90 weeks, with between two and seven sessions per week (median session
duration was between 15 and 120 minutes, including warm-up and cool-down). The intensity of exercise
ranged between 50% and 85% VO2peak (Table 2).
Assessment of study quality and risk of bias in included trials
The overall quality of included trials was judged to be moderate to good, with a median TESTEX score of
11 (range 9–14) out of a maximum score of 15 (Table 3).
TABLE 1 Baseline characteristics of patients in the ExTraMATCH II master data set
Characteristic ExCR (N= 1986) Control (N= 2003) All (N= 3989)
Age (years), mean (SD) 61.4 (12.8) 61.5 (13.1) 61.4 (13.0)
Gender, n (%)
Male 1455 (73.3) 1511 (75.4) 2966 (74.4)
Female 531 (26.7) 492 (24.6) 1023 (25.7)
Baseline ejection fraction (%); mean (SD) 27.2 (8.8) 26.9 (8.7) 26.9 (8.7)
NYHA status, n (%)
Class I 25 (1.3) 29 (1.5) 54 (1.4)
Class II 1124 (58.6) 1148 (59.5) 2272 (59.0)
Class III 721 (37.6) 728 (37.7) 1449 (37.7)
Class IV 47 (2.5) 26 (1.4) 73 (1.9)
Aetiology, n (%)
Ischaemic 1067 (57.3) 1055 (56.1) 2122 (56.7)
Non-ischaemic 796 (42.7) 826 (43.9) 1622 (43.3)
Ethnicity, n (%)
White 1130 (70.2) 1163 (71.8) 2293 (71.0)
Non-white 480 (29.8) 458 (28.3) 938 (29.0)
VO2peak (ml/kg/minute), mean (SD) 14.9 (4.3) 15.0 (4.6) 15.0 (4.4)
Note
Percentages may not sum to 100 because of rounding.
CHARACTERISTICS AND QUALITY OF INCLUDED STUDIES
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TABLE 2 Characteristics of included trials in the ExTraMATCH II master data set
Study characteristic n (%), unless otherwise stated
Publication year
1990–99 2 (10.5)
2000–9 12 (63.2)
2010–12 4 (21.0)
Unpublished 1 (5.3)
Main study location
Europe 14 (73.7)
North Americaa 5 (26.3)
Study centre
Single 13 (68.4)
Multiple 5 (26.3)
Not reported 1 (5.3)
Sample size
0–99 11 (57.9)
100–999 7 (36.8)
≥ 1000 1 (5.3)
Duration of follow-up in data set (months), median (interquartile range)
Mortality 29 (24–40)
Intervention characteristic
Intervention type
Exercise-only programmes 13 (68.4)
Comprehensive programmes 5 (26.3)
Not reported 1 (5.3)
Type of exercise
Aerobic exercise only 12 (63.2)
Aerobic plus resistance training 6 (31.6)
Not reported 1 (5.3)
Dose of intervention
Duration of intervention (weeks), median (range) 30 (15–90)
Frequency (sessions/week), median (range) 2.5 (2–6.5)
Length of exercise session (minutes), median (range) 24 (4–120)
Exercise intensity (range) 50–85% VO2peak
11–15 Borg rating
Setting
Centre based 14 (73.7)
Home based 4 (21.1)
Not reported 1 (5.3)
Borg, Borg Scale of Perceived Exertion.
a HF-ACTION study19 was categorised as North America, but was also delivered to a small number of patients in France.
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TABLE 3 Assessment of quality using TESTEX scale for trials in ExTraMATCH II
First author/
study (year)
Eligibility
criteria
specified
Randomisation
specified
Allocation
concealed
Groups
similar at
baseline
Blinding of
assessors
Outcome
measures in
> 85% of
participantsa
Intention-
to-treat
analysisb
Between-
group
statistical
comparisons
reportedc
Point
measures and
measures of
variability
reported
Activity
monitoring
in control
group
Relative
exercise
intensity
reviewed
Exercise
volume
and
energy
expended
Overall
TESTEX
score
(maximum
score of 15)
Belardinelli et al. (1999)50 1 0 0 1 0 3 1 1 1 0 0 1 9
Belardinelli et al. (2012)56 1 0 0 1 0 3 1 1 1 0 0 1 9
DANREHAB (2008)57 1 1 0 1 1 3 1 2 1 0 0 0 11
Dracup et al. (2007)58 1 0 0 1 0 3 1 2 1 1 1 1 10
Gary et al. (2010)59 1 1 0 1 1 3 1 2 1 0 0 0 11
Giannuzzi et al. (2003)60 1 0 0 1 0 2 1 2 1 0 1 1 10
Hambrecht et al. (2000)51 1 1 0 1 0 3 0 2 1 0 1 1 11
HF-ACTION (2009)19 1 1 1 1 1 3 1 2 1 1 0 1 14
Jolly et al. (2009)61 1 1 1 1 0 2 1 2 1 0 1 1 12
McKelvie et al. (2002)52 1 1 1 1 1 2 1 1 1 0 1 1 12
Mueller et al. (2007)62 1 0 0 1 0 2 1 2 1 0 1 1 10
Nilsson et al. (2008)63 1 1 0 1 1 2 1 2 1 0 0 1 11
Passino et al. (2006)67 1 0 0 1 0 2 1 2 1 0 1 1 10
Wielenga et al. (1999)53 1 0 0 1 0 2 1 2 1 0 0 1 9
Willenheimer et al. (2001)54 1 0 0 1 1 2 1 2 1 0 0 1 9
Witham et al. (2005)64 1 1 0 1 1 3 1 2 1 0 1 0 12
Witham et al. (2012)65 1 1 0 1 1 3 1 2 1 0 1 0 12
Yeh et al. (2011)66 1 1 0 1 1 3 1 2 1 1 0 0 12
Zanelli et al. (1997)55 No scored
DANREHAB, DANish Cardiac ReHABilitation trial.
a Three points possible.
b If intention to treat was not specifically mentioned, but it was noted that no participants withdrew and all were analysed, then 1 point was awarded.
c Two points possible.
d Not scored as no full publication.
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Chapter 5 Impact of exercise-based cardiac
rehabilitation on mortality and hospitalisation
One trial that provided IPD was not included in the mortality and hospitalisation analyses, as no datawere provided to allow calculation of survival time or time to hospitalisation.59 This resulted in the
inclusion of 18 trials,19,50,51,53–58,60–67,73 comprising 3912 patients (1948 ExCR patients and 1964 control
patients), with a median follow-up of 19 months for mortality outcomes and 11 months for hospitalisation
outcomes. Figure 2 summarises the study selection process for the mortality and hospitalisation analyses.
Characteristics of included patients and trials
Patient baseline characteristics were well balanced between ExCR patients and control patients (Table 4).
The majority of patients were male (75%), with a mean age of 61 years (SD 13 years). The mean baseline
left ventricular ejection fraction was 27% (SD 8.1%), no included studies recruited patients with HFpEF
(i.e. an ejection fraction of > 45%), and most patients were in NYHA functional class II (59%) or III (37%).
Studies were published between 1999 and 2012 across a number of countries (see Table 2). Sample size
ranged from 50 to 2130 patients. All trials evaluated an aerobic exercise intervention; six also included
resistance training.52,57,58,61,64,65 Exercise training was most commonly delivered in either an exclusively
centre-based setting or a centre-based setting in combination with some home exercise sessions (Table 5).
Three trials were conducted in an exclusively home-based setting.52,54,58 The dose of exercise training
ranged widely across studies, with an average session duration of 15–120 minutes (including warm-up and
cool-down), two to seven sessions per week, of exercise intensity equivalent of 50–85% VO2peak and
delivery duration of 12–90 weeks.
2014 Cochrane review10
n = 33 trials (n = 46 publications)
ExTraMATCH II IPD meta-analysis
n = 23 trials met inclusion criteria
(n = 4398 patients)
Excluded trials
(n = 14)
RCTs included from
ExTraMATCH18 analysis
n = 4 trials
(n = 4 publications)
Excluded trials
(n = 5)
• < 50 patients, n = 14
• Data sets destroyed/lost, n = 2
• Trial group uncontactable, n = 1
• Patients overlapped in
   another trial, n = 1
• No IPD available on events, n = 1
ExTraMATCH II IPD meta-analysis
n = 18 trials provided data
(n = 3912 patients)
All-cause mortality
IPD analysis
n = 17 trials provided data
(n = 3782 patients)
HF-related mortality
IPD analysis
n = 9 trials provided data
(n = 915 patients)
All-cause admissions
IPD analysis
n = 11 trials provided data
(n = 3190 patients)
HF-related admissions
IPD analysis
n = 13 trials provided data
(n = 3494 patients)
FIGURE 2 The PRISMA flow diagram summarising the selection of studies for mortality and hospitalisation
analyses.
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TABLE 4 Baseline characteristics of patients in the mortality and hospitalisation analyses
Characteristic ExCR (N= 1948) Control (N= 1964) All (N= 3912)
Age (years), mean (SD) 61.3 (12.7) 61.4 (13.2) 61.3 (13.0)
Gender, n (%)
Male 1442 (74) 1489 (76) 2931 (75)
Female 506 (26) 475 (24) 981 (25)
Baseline ejection fraction (%), mean (SD) 26.8 (8.2) 26.7 (8.1) 26.7 (8.1)
NYHA status, n (%)
Class I 25 (1) 28 (1) 53 (1)
Class II 1107 (59) 1130 (60) 2237 (59)
Class III 700 (37) 708 (37) 1408 (37)
Class IV 47 (3) 26 (1) 73 (2)
Aetiology, n (%)
Ischaemic 1094 (57) 1080 (56) 2174 (57)
Non-ischaemic 809 (43) 838 (44) 1647 (43)
Ethnicity, n (%)
White 1100 (70) 1140 (72) 2240 (71)
Non-white 472 (30) 445 (28) 917 (29)
VO2peak (ml/kg/minute), mean (SD) 14.9 (4.4) 15.0 (4.6) 14.9 (4.5)
Note
Percentages may not sum to 100 because of rounding.
TABLE 5 Characteristics of included trials in the mortality and hospitalisation analyses
Study characteristic n (%), unless otherwise stated
Publication year
1990–9 2 (11)
2000–9 12 (67)
2010–12 3 (17)
Unpublished 1 (6)
Main study location
Europe 14 (78)
North Americaa 4 (22)
IMPACT ON MORTALITY AND HOSPITALISATION
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TABLE 5 Characteristics of included trials in the mortality and hospitalisation analyses (continued )
Study characteristic n (%), unless otherwise stated
Study centre
Single 12 (67)
Multiple 5 (28)
Not reported 1 (6)
Sample size
0–99 10 (56)
100–999 7 (39)
≥ 1000 1 (6)
Duration of follow-up in data set (months), median (range)
Mortality 18.6 (11.8–419)
Hospitalisation 11.2 (2.6–98)
Intervention characteristic
Intervention type
Exercise-only programmes 5 (28)
Comprehensive programmes 12 (67)
Not reported 1 (6)
Type of exercise
Aerobic exercise only 12 (67)
Aerobic plus resistance training 6 (33)
Dose of intervention
Duration of intervention (weeks), median (range) 30 (12–90)
Frequency (sessions/week), median (range) 2.8 (2–7)
Length of exercise session (minutes), median (range) 24 (15–120)
Exercise intensity (range) 40–80% maximum heart rate
50–85% VO2peak
12–18 Borg rating
Setting
Centre based 6 (33)
Home based 3 (17)
Centre and home based 8 (44)
Not reported 1 (6)
Borg, Borg Scale of Perceived Exertion.
a HF-ACTION study19 was categorised as North America, but was also delivered to a small number of patients in France.
Note
Percentages may not sum to 100 because of rounding.
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Assessment of study quality and risk of bias
There was no evidence of significant small-study bias for the four outcomes (Figure 3). The overall quality
of included trials was judged to be moderate to good, with a median TESTEX31 score of 11 (range 9–14)
out of a maximum score of 15 (Table 6). The criteria of allocation concealment and physical activity
monitoring in the control groups were met in only three studies;19,58,66 the other TESTEX criteria were met
in ≥ 50% of the trials.
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FIGURE 3 Funnel plots for mortality and hospitalisation analyses. (a) All-cause mortality, Egger’s test –0.26,
p= 0.458; (b) HF-specific mortality, Egger’s test –1.60, p= 0.147; (c) all-cause hospitalisation, Egger’s test 0.16,
p= 0.739; and (d) HF-specific hospitalisation, Egger’s test 0.32, p= 0.610. (continued )
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Findings
Primary analysis
Compared with control, all time-to-event mean treatment effects from the two-stage random-effects IPD
meta-analysis were in favour of ExCR, but had wide CIs and were not statistically significant [all-cause mortality:
HR 0.83 (95% CI 0.67 to 1.04; p = 0.107, 17 studies,19,50–55,57,58,60–67 3782 patients, τ2 = 0.04, I2 = 26%);
HF-specific mortality: HR 0.84 (95% CI 0.48 to 1.46; p = 0.527, 9 studies,51–54,58,60,64,65,67 915 patients, τ2 = 0.00,
I2 = 0%); all-cause hospitalisation: HR 0.90 (95% CI 0.76 to 1.06; p = 0.210, 11 studies,19,51,54,55,57,58,60,61,64–66
3190 patients, τ2 = 0.01, I2 = 12.4%); and HF-specific hospitalisation: HR 0.98 (95% CI 0.72 to 1.35;
p = 0.902, 13 studies,19,50,51,52,56–58,60,61,64–67 3494 patients, τ2 = 0.10, I2 = 45%)] (Figure 4 and Tables 7–10).
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FIGURE 3 Funnel plots for mortality and hospitalisation analyses. (a) All-cause mortality, Egger’s test –0.26,
p= 0.458; (b) HF-specific mortality, Egger’s test –1.60, p= 0.147; (c) all-cause hospitalisation, Egger’s test 0.16,
p= 0.739; and (d) HF-specific hospitalisation, Egger’s test 0.32, p= 0.610.
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TABLE 6 Assessment of quality using TESTEX scale31 of included studies in mortality and hospitalisation analysis
First author/
study (year)
Eligibility
criteria
specified
Randomisation
specified
Allocation
concealed
Groups
similar at
baseline
Blinding of
assessors
Outcome
measures in
> 85% of
participantsa
Intention-
to-treat
analysisb
Between-
group
statistical
comparisons
reportedc
Point
measures and
measures of
variability
reported
Activity
monitoring
in control
group
Relative
exercise
intensity
reviewed
Exercise
volume
and
energy
expended
Overall
TESTEX
score
(maximum
score of 15)
Belardinelli et al. (1999)50 1 0 0 1 0 3 1 1 1 0 0 1 9
Belardinelli et al. (2012)56 1 0 0 1 0 3 1 1 1 0 0 1 9
DANREHAB (2008)57 1 1 1 1 1 3 1 2 1 0 0 0 12
Dracup et al. (2007)58 1 0 0 1 0 3 1 2 1 1 1 1 10
Giannuzzi et al. (2003)60 1 0 0 1 0 2 1 2 1 0 1 1 10
Hambrecht et al. (2000)51 1 1 0 1 0 3 0 2 1 0 1 1 11
HF-ACTION (2009)19 1 1 1 1 1 3 1 2 1 1 0 1 14
Jolly et al. (2009)61 1 1 1 1 0 2 1 2 1 0 1 1 12
McKelvie et al. (2002)52 1 1 1 1 1 2 1 1 1 0 1 1 12
Mueller et al. (2007)62 1 0 0 1 0 2 1 2 1 0 1 1 10
Nilsson et al. (2008)63 1 1 0 1 1 2 1 2 1 0 0 1 11
Passino et al. (2006)67 1 0 0 1 0 2 1 2 1 0 1 1 10
Wielenga et al. (1999)53 1 0 0 1 0 2 1 2 1 0 0 1 9
Willenheimer et al. (2001)54 1 0 0 1 1 2 1 2 1 0 0 1 9
Witham et al. (2005)64 1 1 0 1 1 3 1 2 1 0 1 0 12
Witham et al. (2012)65 1 1 0 1 1 3 1 2 1 0 1 0 12
Yeh et al. (2011)66 1 1 0 1 1 3 1 2 1 1 0 0 12
Zanelli et al. (1997)55 No scored
DANREHAB, DANish Cardiac ReHABilitation trial.
a Three points possible.
b If intention to treat was not specifically mentioned, but it was noted that no participants withdrew and all were analysed, then 1 point was awarded.
c Two points possible.
d Not scored as no full publication.
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Overall (I 2 = 25.7%; p = 0.171)
Zanelli (1997)55
Witham (2012)65
Witham (2005)64
Willenheimer (2001)54
Wielenga (1999)53
Passino (2006)67
Nilsson (2008)63
Mueller (2007)62
McKelvie (2002)52
Jolly (2009)61
HF-ACTION (2009)19
Hambrecht (2000)51
Dracup (2007)58
DANREHAB (2008)57
Belardinelli (1999)50
0.83 (0.67 to 1.04)
0.45 (0.21 to 0.95)
2.09 (0.19 to 23.03)
0.29 (0.03 to 2.84)
1.37 (0.59 to 3.17)
1.09 (0.61 to 1.96)
0.48 (0.23 to 0.97)
0.94 (0.59 to 1.49)
0.78 (0.33 to 1.85)
0.98 (0.52 to 1.84)
1.62 (0.45 to 5.78)
0.92 (0.75 to 1.13)
0.93 (0.13 to 6.65)
1.16 (0.51 to 2.64)
1.35 (0.30 to 6.04)
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FIGURE 4 Effect of ExCR on mortality and hospitalisation across patient subgroups: two-stage IPD meta-analysis.
(a) All-cause mortality; (b) HF-specific mortality; (c) all-cause hospitalisation; and (d) HF-specific hospitalisation.
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(a) All-cause mortality; (b) HF-specific mortality; (c) all-cause hospitalisation; and (d) HF-specific hospitalisation.
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TABLE 7 All-cause mortality: overall treatment effect and subgroup (interaction) effects
Baseline variable
Primary analysis,
HR (95% CI); p-value
Secondary analysis,
HR (95% CI); p-value Sensitivity analyses, HR (95% CI); p-value
Two-stage model,
random effects
One-stage Cox
model, stratified by
study with fixed
treatment effect
Two-stage model,
random effects
excluding
HF-ACTION19
One-stage Cox
model, stratified
by study with
fixed effect
excluding
HF-ACTION19
Two-stage model,
random effects
1-year truncation
Two-stage model,
random effects
2-year truncation
Two-stage model,
random effects
5-year truncation
Overall effect 0.83 (0.67 to 1.04);
0.107
0.85 (0.73 to 0.99);
0.034
0.81 (0.61 to 1.06);
0.129
0.79 (0.64 to 0.97);
0.027
0.87 (0.58 to 1.31);
0.507
0.86 (0.67 to 1.10);
0.217
0.84 (0.66 to 1.06);
0.140
Interaction term
Age (years) 0.99 (0.98 to 1.00);
0.165
0.99 (0.98 to 1.01);
0.254
0.98 (0.96 to 1.01);
0.144
0.99 (0.96 to 1.01);
0.228
0.98 (0.95 to 1.00);
0.077
0.98 (0.96 to 1.00);
0.034
0.99 (0.97 to 1.00);
0.097
Gender (male vs. female) 1.10 (0.73 to 1.66);
0.660
1.06 (0.70 to 1.60);
0.783
0.71 (0.35 to 1.43);
0.341
0.70 (0.36 to 1.36);
0.300
0.76 (0.34 to 1.68);
0.490
0.96 (0.55 to 1.67);
0.872
1.17 (0.75 to 1.82);
0.481
Ejection fraction (%) 0.99 (0.97 to 1.01);
0.250
0.99 (0.97 to 1.01);
0.332
0.98 (0.95 to 1.01);
0.124
0.98 (0.96 to 1.01);
0.201
1.04 (1.00 to 1.08);
0.055
0.99 (0.97 to 1.02);
0.688
0.99 (0.97 to 1.01);
0.506
NYHA class (NYHA class I/II
vs. NYHA class III/IV)
0.80 (0.58 to 1.11);
0.182
0.79 (0.57 to 1.08);
0.134
0.82 (0.49 to 1.38);
0.459
0.75 (0.46 to 1.22);
0.244
0.50 (0.23 to 1.07);
0.073
0.84 (0.54 to 1.30);
0.431
0.83 (0.59 to 1.18);
0.297
HF aetiology (ischaemic vs.
non-ischaemic)
0.73 (0.38 to 1.39);
0.335
1.19 (0.86 to 1.64);
0.297
0.69 (0.36 to 1.31);
0.255
0.87 (0.54 to 1.41);
0.575
0.69 (0.19 to 2.54);
0.574
0.79 (0.38 to 1.67);
0.542
0.70 (0.33 to 1.47);
0.345
Ethnic group (white vs.
non-white)
1.12 (0.74 to 1.69);
0.593
1.11 (0.74 to 1.68);
0.604
a 1.05 (0.25 to 4.31);
0.949
0.72 (0.34 to 1.53);
0.396
0.83 (0.50 to 1.38);
0.468
1.12 (0.74 to 1.69);
0.593
Exercise capacity
Baseline VO2peak directly
measured
1.00 (0.95 to 1.05);
0.937
0.99 (0.95 to 1.04);
0.783
0.98 (0.90 to 1.08);
0.712
0.99 (0.91 to 1.07);
0.777
0.97 (0.88 to 1.06);
0.456
0.99 (0.93 to 1.05);
0.780
0.98 (0.91 to 1.06);
0.630
Baseline VO2peak directly
measured and predicted
1.00 (0.95 to 1.06);
0.903
1.00 (0.96 to 1.04);
0.954
1.00 (0.91 to 1.08);
0.923
1.00 (0.93 to 1.07);
0.984
0.99 (0.90 to 1.08);
0.734
1.00 (0.94 to 1.06);
0.961
1.00 (0.93 to 1.07);
0.924
Standardised scores using
baseline VO2peak, 6MWT,
ISWT units and watts score
1.03 (0.83 to 1.27);
0.802
1.02 (0.85 to 1.22);
0.851
0.99 (0.71 to 1.39);
0.955
1.01 (0.75 to 1.35);
0.967
0.97 (0.66 to 1.41);
0.858
1.00 (0.78 to 1.30);
0.972
1.01 (0.76 to 1.35);
0.938
a Study estimate not available as too few studies provide data.
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TABLE 8 Heart failure-specific mortality: overall treatment effect and subgroup (interaction) effects
Baseline variable
Primary analysis,
HR (95% CI); p-value
Secondary analysis,
HR (95% CI); p-value Sensitivity analyses, HR (95% CI); p-value
Two-stage model,
random effects
One-stage Cox model,
stratified by study with
fixed treatment effect
Two-stage model,
random effects
1-year truncation
Two-stage model,
random effects
2-year truncation
Two-stage model,
random effects
5-year truncation
Overall effect 0.84 (0.48 to 1.46);
0.527
0.75 (0.44 to 1.28);
0.294
a 1.30 (0.59 to 2.87);
0.515
0.84 (0.49 to 1.53);
0.575
Interaction term
Age (years) 0.96 (0.91 to 1.02);
0.206
0.96 (0.92 to 1.01);
0.162
a 0.91 (0.84 to 0.98);
0.017
0.95 (0.90 to 1.00);
0.066
Gender (male vs. female) 0.53 (0.08 to 3.73);
0.524
0.61 (0.11 to 3.49);
0.583
a b b
Ejection fraction (%) 0.95 (0.89 to 1.02);
0.159
0.96 (0.90 to 1.02);
0.179
a 1.01 (0.82 to 1.24);
0.912
0.96 (0.89 to 1.04);
0.309
NYHA class (NYHA class I/II vs. NYHA class III/IV) 0.54 (0.07 to 4.28);
0.562
0.78 (0.23 to 26.65);
0.691
a b 0.54 (0.07 to 4.28);
0.562
HF aetiology (ischaemic vs. non-ischaemic) Data only available for
one study
3.30 (1.02 to 10.7);
0.047
a b b
Ethnic group (white vs. non-white) b b a b b
Exercise capacity
Baseline VO2peak directly measured 0.90 (0.76 to 1.07);
0.232
0.93 (0.78 to 1.09);
0.362
a 0.98 (0.73 to 1.31);
0.893
0.86 (0.69 to 1.06);
0.146
Baseline VO2peak directly measured and
predicted
0.91 (0.77 to 1.07);
0.263
0.94 (0.80 to 1.10);
0.423
a 0.98 (0.76 to 1.26);
0.854
0.88 (0.72 to 1.06);
0.184
Standardised scores using baseline VO2peak,
6MWT, ISWT units and watts score
0.69 (0.35 to 1.35);
0.276
0.82 (0.43 to 1.56);
0.545
a 0.86 (0.31 to 2.37);
0.773
0.61 (0.28 to 1.32);
0.210
a HF-ACTION19 did not provide HF mortality so sensitivity analysis of omission not undertaken.
b Study estimate not available as too few studies provide data.
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TABLE 9 All-cause hospitalisation: overall treatment effect and subgroup (interaction) effects
Baseline variable
Primary analysis,
HR (95% CI); p-value
Secondary analysis,
HR (95% CI); p-value Sensitivity analyses, HR (95% CI); p-value
Two-stage model,
random effects
One-stage Cox
model, stratified by
study with fixed
treatment effect
Two-stage model,
random effects
excluding
HF-ACTION19
One-stage Cox
model, stratified
by study with
fixed treatment
effect excluding
HF-ACTION19
Two-stage model,
random effects
1-year truncation
Two-stage model,
random effects
2-year truncation
Two-stage model,
random effects
5-year truncation
Overall effect 0.90 (0.76 to 1.06);
0.210
0.91 (0.83 to 1.01);
0.072
0.86 (0.64 to 1.14);
0.293
0.85 (0.68 to 1.09);
0.210
0.94 (0.75 to 1.18);
0.583
0.91 (0.74 to 1.11);
0.330
0.90 (0.76 to 1.06);
0.210
Interaction term
Age (years) 1.00 (0.99 to 1.01);
0.794
1.00 (0.99 to 1.01);
0.854
1.00 (0.98 to 1.03);
0.808
1.00 (0.98 to 1.02);
–0.969
1.00 (0.99 to 1.01);
0.636
1.00 (0.99 to 1.01);
0.798
1.00 (0.99 to 1.01);
0.794
Gender (male vs. female) 1.09 (0.87 to 1.36);
0.454
1.09 (0.88 to 1.36);
0.424
0.66 (0.38 to 1.14);
0.136
0.68 (0.39 to 1.16);
0.158
1.05 (0.80 to 1.37);
0.745
1.15 (0.91 to 1.46);
0.239
1.09 (0.87 to 1.35);
0.454
Ejection fraction (%) 1.00 (0.98 to 1.01);
0.629
1.00 (0.98 to 1.01);
0.646
1.00 (0.96 to 1.04);
0.857
1.00 (0.96 to 1.05);
0.831
1.00 (0.98 to 1.01);
0.632
0.99 (0.98 to 1.01);
0.343
1.00 (0.98 to 1.01);
0.629
NYHA class (NYHA class I/II
vs. NYHA class III/IV)
0.91 (0.74 to 1.12);
0.370
0.90 (0.73 to 1.10);
0.308
0.89 (0.43 to 1.87);
0.763
0.79 (0.39 to 1.60);
0.508
0.81 (0.63 to 1.05);
0.110
0.87 (0.70 to 1.09);
0.235
0.91 (0.74 to 1.12);
0.355
HF aetiology (ischaemic vs.
non-ischaemic)
0.96 (0.71 to 1.31);
0.810
1.00 (0.82 to 1.22);
0.988
0.73 (0.39 to 1.39);
0.340
0.73 (0.40 to 1.31);
0.284
1.08 (0.84 to 1.38);
0.562
1.04 (0.84 to 1.29);
0.723
1.01 (0.83 to 1.24);
0.910
Ethnic group (white vs.
non-white)
1.02 (0.83 to 1.26);
0.860
1.02 (0.83 to 1.26);
0.852
1.02 (0.47 to 2.21);
0.959
1.06 (0.49 to 2.32);
0.879
1.14 (0.88 to 1.48);
0.322
1.06 (0.85 to 1.33);
0.607
1.02 (0.83 to 1.26);
0.860
Exercise capacity
Baseline VO2peak directly
measured
1.01 (0.99 to 1.04);
0.259
1.02 (0.99 to 1.04);
0.234
1.05 (0.95 to 1.16);
0.352
1.06 (0.96 to 1.17);
0.262
1.03 (0.99 to 1.06);
0.124
1.02 (0.99 to 1.04);
0.243
1.01 (0.99 to 1.04);
0.259
Baseline VO2peak directly
measured and predicted
1.02 (0.99 to 1.04);
0.153
1.02 (0.99 to 1.04);
0.134
1.07 (0.98 to 1.17);
0.125
1.08 (0.99 to 1.17);
0.078
1.03 (1.00 to 1.06);
0.057
1.02 (0.99 to 1.05);
0.129
1.02 (0.99 to 1.04);
0.153
Standardised scores using
baseline VO2peak, 6MWT,
ISWT units and watts score
1.09 (0.98 to 1.22);
0.095
1.10 (0.99 to 1.22);
0.088
1.30 (0.93 to 1.83);
0.120
1.32 (0.95 to 1.82);
0.097
1.16 (1.02 to 1.33);
0.027
1.11 (0.99 to 1.24);
0.077
1.09 (0.98 to 1.22);
0.095
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TABLE 10 Heart failure-specific hospitalisation: overall treatment effect and subgroup (interactions) effects in studies included in IPD meta-analysis
Baseline variable
Primary analysis,
HR (95% CI); p-value
Secondary analysis,
HR (95% CI); p-value Sensitivity analyses, HR (95% CI); p-value
Two-stage model,
random effects
One-stage Cox
model, stratified by
study with fixed
treatment effect
Two-stage model,
random effects
excluding
HF-ACTION19
One-stage Cox
model, stratified
by study with
fixed treatment
effect excluding
HF-ACTION19
Two-stage model,
random effects
1-year truncation
Two-stage model,
random effects
2 year truncation
Two-stage model,
random effects
5 year truncation
Overall effect 0.98 (0.72 to 1.35);
0.902
0.94 (0.81 to 1.08);
0.368
1.00 (0.65 to 1.54);
0.999
1.03 (0.79 to 1.35);
0.829
1.08 (0.88 to 1.33);
0.470
1.06 (0.83 to 1.34);
0.658
0.97 (0.70 to 1.34);
0.855
Interaction term
Age (years) 1.00 (0.99 to 1.02);
0.603
1.00 (0.99 to 1.02);
0.632
1.00 (0.98 to 1.03);
0.958
1.00 (0.97 to 1.02);
0.906
1.00 (0.99 to 1.02);
0.640
1.00 (0.99 to 1.02);
0.611
1.00 (0.99 to 1.02);
0.580
Gender (male vs. female) 1.03 (0.73 to 1.46);
0.865
0.99 (0.71 to 1.39);
0.949
0.70 (0.32 to 1.53);
0.372
0.65 (0.33 to 1.29);
0.215
0.76 (0.46 to 1.24);
0.274
1.06 (0.68 to 1.66);
0.803
0.93 (0.49 to 1.75);
0.815
Ejection fraction (%) 0.51 (0.14 to 1.79);
0.291
0.99 (0.97 to 1.01);
0.325
0.99 (0.96 to 1.03);
0.540
0.99 (0.97 to 1.01);
0.350
0.99 (0.97 to 1.02);
0.569
0.99 (0.97 to 1.01);
0.350
0.99 (0.97 to 1.02);
0.569
NYHA class (NYHA class I/II
vs. NYHA class III/IV)
1.55 (0.79 to 3.02);
0.200
1.14 (0.84 to 1.54);
0.399
2.05 (0.86 to 4.92);
0.107
1.74 (0.92 to 3.29);
0.089
0.81 (0.51 to 1.29);
0.375
1.17 (0.68 to 2.03);
0.573
1.21 (0.72 to 2.04);
0.475
HF aetiology (ischaemic vs.
non-ischaemic)
1.20 (0.64 to 2.25);
0.577
1.28 (0.94 to 1.74);
0.111
0.95 (0.31 to 2.95);
0.928
1.10 (0.57 to 2.16);
0.771
1.47 (0.94 to 2.29);
0.128
1.28 (0.90 to 1.84);
0.172
1.29 (0.79 to 2.12);
0.309
Ethnic group (white vs.
non-white)
1.18 (0.85 to 1.65);
0.318
1.19 (0.86 to 1.66);
0.291
a 1.79 (0.60 to 5.37);
0.301
1.25 (0.79 to 1.98);
0.334
1.20 (0.83 to 1.74);
0.327
1.18 (0.85 to 1.65);
0.318
Exercise capacity
Baseline VO2peak directly
measured
0.97 (0.88 to 1.07);
0.538
0.97 (0.93 to 1.01);
0.149
0.94 (0.80 to 1.11);
0.467
0.98 (0.90 to 1.07);
0.658
0.99 (0.90 to 1.10);
0.882
0.99 (0.93 to 1.06);
0.769
0.98 (0.89 to 1.08);
0.685
Baseline VO2peak directly
measured and predicted
0.97 (0.89 to 1.07);
0.539
0.97 (0.93 to 1.01);
0.116
0.95 (0.82 to 1.10);
0.483
0.97 (0.89 to 1.05);
0.424
0.98 (0.92 to 1.05);
0.610
0.99 (0.94 to 1.03);
0.535
0.98 (0.90 to 1.07);
0.670
Standardised scores using
baseline VO2peak, 6MWT,
ISWT units and watts score
0.88 (0.62 to 1.26);
0.483
0.86 (0.72 to 1.03);
0.093
0.83 (0.46 to 1.49);
0.527
0.81 (0.56 to 1.16);
0.246
0.92 (0.69 to 1.23);
0.576
0.93 (0.75 to 1.16);
0.517
0.91 (0.69 to 1.20);
0.505
a Study estimate not available as too few studies provide data.
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Interaction analyses for the two-stage model revealed no consistent interaction between the effect of
ExCR and any of the predefined subgroups (age, sex, ejection fraction, NYHA class, HF aetiology, ethnicity
or baseline exercise capacity) for all-cause mortality, HF-related mortality, all-cause hospitalisation or
HF-related hospitalisation (see Tables 7–10). In order to make further comparisons of mortality and
hospitalisation rates within each subgroup, the HR and associated 95% CI from individual subgroup
one-stage IPD meta-analyses are shown in Figure 5. The p-values from the interaction test in the two-stage
IPD meta-analyses are presented alongside these estimates.
0.5 1.0
Favours exercise Favours control
2.0
Age (years)
< 62
≥ 62
Sex
Male
Female
Ejection fraction (%)
< 26
≥ 26
NYHA class
I/II
III/IV
HF aetiology
Ischaemic
Non-ischaemic
Ethnic group
White
Non-white
Exercise capacity (ml/kg/minute)
VO2peak < 14.6
VO2peak ≥ 14.6
 
1.00 (0.69 to 1.45)
0.79 (0.65 to 0.96)
 
0.82 (0.65 to 1.04)
0.87 (0.59 to 1.27)
 
0.93 (0.67 to 1.30)
0.80 (0.63 to 1.00)
 
0.93 (0.70 to 1.23)
0.77 (0.61 to 0.97)
 
0.79 (0.55 to 1.12)
0.88 (0.68 to 1.15)
 
0.91 (0.74 to 1.12)
0.87 (0.64 to 1.20)
 
0.74 (0.5 to 1.09)
0.96 (0.72 to 1.28)
0.165
 
0.660
 
 
0.250
 
 
0.182
 
 
0.335
 
 
0.593
 
0.937
Overall
HR (95% CI)
0.83 (0.67 to 1.04)
(a)
p-value for interactiona
FIGURE 5 Effect of ExCR on mortality and hospitalisation across patient subgroups: individual subgroup one-stage
IPD meta-analyses. (a) All-cause mortality; (b) HF-related mortality; (c) all-cause hospitalisation; and (d) HF-related
hospitalisation. a, Although stratified meta-analyses are shown, the interaction p-values are calculated based on
continuous distribution of age, ejection fraction and baseline exercise capacity. (continued )
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0.25 0.50 1.00
Favours exercise Favours control
4.002.00
Age (years)
< 62
≥ 62
Sex
Male
Female
Ejection fraction (%)
< 26
≥ 26
NYHA class
I/II
III/IV
HF aetiology
Ischaemic
Non-ischaemic
Ethnic group
White
Non-white
Exercise capacity (ml/kg/minute)
VO2peak < 14.6
VO2peak ≥ 14.6
 
1.37 (0.59 to 3.20)
0.60 (0.22 to 1.68)
 
0.77 (0.43 to 1.40)
2.00 (0.32 to 1.24)
 
1.54 (0.65 to 3.67)
0.68 (0.32 to 1.47)
 
0.87 (0.33 to 2.27)
0.96 (0.47 to 1.94)
 
0.98 (0.30 to 3.18)
Not estimable
 
1.04 (0.47 to 2.28)
Not estimable
 
0.89 (0.35 to 2.28)
0.55 (0.18 to 1.74)
0.206
 
0.524
 
 
0.159
 
 
0.562
 
 
Insufficient data to
calculate
 
Insufficient data to
calculate
 
0.232
Overall
HR (95% CI)
0.84 (0.48 to 1.46)
(b)
p-value for interactiona
0.5 1.0
Favours exercise Favours control
2.0
Age (years)
< 62
≥ 62
Sex
Male
Female
Ejection fraction (%)
< 26
≥ 26
NYHA class
I/II
III/IV
HF aetiology
Ischaemic
Non-ischaemic
Ethnic group
White
Non-white
Exercise capacity (ml/kg/minute)
VO2peak < 14.6
VO2peak ≥ 14.6
 
0.94 (0.82 to 1.08)
0.84 (0.66 to 1.06)
 
0.85 (0.69 to 1.06)
0.90 (0.72 to 1.12)
 
0.86 (0.66 to 1.13)
0.87 (0.53 to 1.42)
 
0.94 (0.83 to 1.08)
0.82 (0.58 to 1.15)
 
0.85 (0.65 to 1.10)
0.92 (0.79 to 1.06)
 
0.94 (0.83 to 1.07)
0.93 (0.79 to 1.09)
 
0.83 (0.53 to 1.30)
0.98 (0.83 to 1.15)
0.794
 
0.454
 
 
0.629
 
 
0.370
 
 
0.810
 
 
0.860
 
0.259
Overall
HR (95% CI)
0.90 (0.76 to 1.06)
(c)
p-value for interactiona
FIGURE 5 Effect of ExCR on mortality and hospitalisation across patient subgroups: individual subgroup one-stage
IPD meta-analyses. (a) All-cause mortality; (b) HF-related mortality; (c) all-cause hospitalisation; and (d) HF-related
hospitalisation. a, Although stratified meta-analyses are shown, the interaction p-values are calculated based on
continuous distribution of age, ejection fraction and baseline exercise capacity. (continued )
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Secondary analyses
These primary analysis results were broadly consistent across secondary analyses.
Sensitivity analyses
In sensitivity analyses, four weak interaction effects (p < 0.05) were seen:
1. Age compared with all-cause mortality (p = 0.034) in the two-stage 2-year truncation model (i.e. larger
reduction in all-cause mortality with ExCR in older patients).
2. Age compared with HF-related mortality (p = 0.017) in the two-stage 2-year truncation model
(i.e. larger reduction in HF-related mortality with ExCR in older patients).
3. Ischaemic status compared with HF-related mortality (p = 0.047) in the one-stage model (i.e. larger
reduction in HF-related mortality with ExCR in ischaemic patients).
4. Standardised baseline exercise capacity compared with all-cause hospitalisation (p = 0.027) in the
two-stage 1-year truncation model (i.e. larger reduction in all-cause hospitalisation with ExCR in
patients with lower than average baseline exercise capacity) (see Tables 7–10).
Inferences did not change following the addition of trial-level data from trials that met the study inclusion
criteria but did not contribute IPD (data are not shown here, but are available from the authors of this report).
0.5 1.0
Favours exercise Favours control
2.0
Age (years)
< 62
 ≥  62
Sex
Male
Female
Ejection fraction (%)
< 26
≥ 26
NYHA class
I/II
III/IV
HF aetiology
Ischaemic
Non-ischaemic
Ethnic group
White
Non-white
Exercise capacity (ml/kg/minute)
VO2peak <14.6
VO2peak ≥ 14.6
 
 
0.88 (0.61 to 1.26)
1.00 (0.81 to 1.23)
 
0.90 (0.67 to 1.22)
0.96 (0.65 to 1.43)
 
0.99 (0.76 to 1.28)
0.82 (0.58 to 1.17)
 
0.83 (0.52 to 1.33)
1.12 (0.69 to 1.81)
 
0.94 (0.62 to 1.44)
0.82 (0.65 to 1.04)
 
1.08 (0.85 to 1.37)
0.86 (0.67 to 1.08)
 
0.97 (0.80 to 1.16)
0.77 (0.44 to 1.36)
0.603
 
0.865
 
 
0.291
 
 
0.200
 
 
0.577
 
 
0.318
 
0.538
Overall
HR (95% CI)
0.98 (0.72 to 1.35)
(d)
p-value for interactiona
FIGURE 5 Effect of ExCR on mortality and hospitalisation across patient subgroups: individual subgroup one-stage
IPD meta-analyses. (a) All-cause mortality; (b) HF-related mortality; (c) all-cause hospitalisation; and (d) HF-related
hospitalisation. a, Although stratified meta-analyses are shown, the interaction p-values are calculated based on
continuous distribution of age, ejection fraction and baseline exercise capacity.
DOI: 10.3310/hta23250 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 25
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Taylor et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
31

Chapter 6 Impact of exercise-based cardiac
rehabilitation on health-related quality of life and
exercise capacity
S ix trials that provided IPD but had no data on HRQoL or exercise capacity were excluded from analysesin this section.50,52,54,55,57,73 In addition to comparing usual care with an intervention arm of usual care
plus ExCR, Gary et al.59 also compared the effects of cognitive–behavioural therapy to cognitive–behavioural
therapy plus ExCR. For the purpose of analysis from this point forward, this will be described as one trial
providing two comparisons. For analysis, the data set was split into two and analysed as if the data were
provided by two separate trials. For the HRQoL analysis, nine trials19,58,59,61,63–67 (10 comparisons) provided
data for 3000 patients (1496 ExCR patients and 1504 control patients), with a median follow-up of 33 weeks.
For the exercise capacity analysis, 13 trials19,51,56,58–67 (14 comparisons) provided data for 3332 patients
(1662 ExCR patients and 1670 control patients), with a median follow-up of 26 weeks. Figure 6 summarises
the study selection process.
Characteristics of included patients and trials
Patient baseline characteristics were well balanced between ExCR patients and control patients (Table 11).
The majority of patients were male (73%), with a mean age of 61 years. The mean baseline left ventricular
ejection fraction was 27%, < 5% of included patients had a HFpEF (defined as an ejection fraction of
> 45%), and most patients were in NYHA functional class II (62%) or III (36%). Studies were published
between 2000 and 2012 across a number of countries (Table 12). Sample size ranged from 50 to 2130
patients. All trials evaluated an aerobic exercise intervention; four also included resistance training.58,61,64,65
Exercise training was most commonly delivered in an exclusively centre-based setting. Four trials were
conducted in an exclusively home-based setting.58,59,61,67 The dose of exercise training ranged across
studies, with an average session duration of 15–60 minutes (including warm-up and cool-down), of two
to seven sessions per week, exercise intensity equivalent of 40–70% VO2peak and delivery duration of
4–120 weeks.
Assessment of study quality and risk of bias
There was no evidence of significant small-study bias for the five outcomes studied (Figure 7). The overall quality
of included trials was judged to be moderate to good, with a median TESTEX31 score of 11 (range 9–14)
out of a maximum score of 15 (Table 13). The criteria of allocation concealment and physical activity
monitoring in the control groups were met in only two19,61 and three studies,19,58,66 respectively. The other
TESTEX criteria were each met in ≥ 50% of trials.
Findings
Primary analysis
Compared with control, treatment effects from the one-stage meta-analysis at the 12-month follow-up
showed a significant improvement with ExCR in exercise capacity as assessed by the 6MWT (mean difference
21.0 m, 95% CI 1.57 to 40.4 m; p = 0.034, τ2 = 491, I2 = 78%) and standardised exercise capacity score
(mean difference 0.27 SD units, 95% CI 0.11 to 0.43; p = 0.001, τ2 = 0.08, I2 = 91%). No significant difference
in VO2peak at 12 months was observed (1.01 ml/kg/minute, 95% CI –0.42 to 2.44 ml/kg/minute; p = 0.168,
τ2 = 2.17, I2 = 94%).
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2014 Cochrane review10
n = 33 trials (n = 46 publications)
ExTraMATCH II IPD meta-analysis
n = 23 trials met inclusion criteria
(n = 4398 patients)
RCTs included from
ExTraMATCH18 analysis
n = 4 trials
(n = 4 publications)
Excluded trials
(n = 14)
• < 50 patients in trial, n = 14
ExTraMATCH II IPD meta-analysis
n = 19 trials (3990 patients) provided data
n = 13 trials (14 comparisons, 3332 patients) provided either HRQoL or exercise capacity data
Exercise capacity IPD meta-analysis
VO2peak, directly reported
n = 7 trials provided data (2685 patients) provided data
6MWT, directly reported
n = 8 trials provided data (2717 patients) provided data
Excluded trials
(n = 4)
• Data sets destroyed/lost, n = 2
• Trial group uncontactable, n = 1
• Patients duplicated in another study, n = 1
HRQoL IPD meta-analysis
MLHFQ
n = 8 trials provided data (759 patients) provided data
All HRQoL outcomes
n = 9 trials, 10 comparisons (2970 patients) provided data
FIGURE 6 The PRISMA flow diagram summarising the selection of studies for HRQoL and exercise capacity analyses.
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TABLE 11 Baseline characteristics of patients in the HRQoL and exercise capacity analyses
Characteristic
Intervention
All (N= 3332)ExCR (N= 1662) Control (N= 1670)
Age (years), mean (SD) 60.9 (13.2) 61.2 (13.5) 61.1 (13.4)
Gender, n (%)
Male 1187 (71.4) 1237 (74.1) 2424 (72.8)
Female 475 (28.6) 433 (25.9) 908 (27.3)
Baseline ejection fraction (%), mean (SD) 27.0 (8.8) 26.9 (8.7) 26.9 (8.8)
Baseline ejection fraction, n (%)
HFrEF (< 45%) 1721 (96.8) 1744 (97.5) 3465 (97.1)
HFpEF (≥ 45%) 57 (3.2) 45 (2.5) 102 (2.9)
NYHA status, n (%)
Class I 20 (1.2) 25 (1.5) 45 (1.4)
Class II 1002 (61) 1032 (63) 2034 (62.0)
Class III 597 (36) 569 (35) 1166 (35.5)
Class IV 19 (1.2) 18 (1.1) 37 (1.1)
Aetiology, n (%)
Ischaemic 892 (54.9) 884 (54.1) 1776 (54.5)
Non-ischaemic 732 (45.1) 750 (45.9) 1482 (45.5)
Ethnicity, n (%)
White 1085 (69.3) 1117 (70.9) 2202 (70.1)
Non-white 480 (30.7) 458 (29.1) 938 (30.0)
VO2peak (ml/kg/minute), mean (SD) 15.0 (4.5) 15.1 (4.7) 15.0 (4.6)
6MWT (m), mean (SD) 362.6 (109.3) 362.5 (112.1) 362.6 (110.7)
TABLE 12 Characteristics of included trials in the HRQoL and exercise capacity analyses
Study characteristic n (%), unless otherwise stated
Publication year
1990–9 0 (0)
2000–9 9 (64)
2010–12 5 (36)
Unpublished 0 (0)
Main study location
Europe 9 (64)
North Americaa 5 (36)
continued
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TABLE 12 Characteristics of included trials in the HRQoL and exercise capacity analyses (continued )
Study characteristic n (%), unless otherwise stated
Study centre
Single 10 (71.4)
Multiple 4 (28.6)
Not reported 0 (0)
Sample size
0–99 8 (57)
100–999 5 (36)
≥ 1000 1 (7)
Duration of latest follow-up (weeks), median (range)
HRQoL outcomes 33 (26–104)
Exercise capacity outcomes 26 (9–520)
Intervention characteristic
Intervention type
Exercise-only programmes 9 (64.3)
Comprehensive programmes 5 (35.7)
Type of exercise
Aerobic exercise only 10 (71.4)
Aerobic plus resistance training 4 (28.6)
Dose of intervention
Duration of intervention (weeks), median (range) 24 (4–120)
Frequency (sessions/week), median (range) 3 (2–6.5)
Length of exercise session (minutes), median (range) 30 (15–60)
Exercise intensity (range) 40–70% VO2peak
11–15 Borg rating
Setting
Centre based 9 (64.3)
Home based 5 (35.7)
Borg, Borg Scale of Perceived Exertion.
a HF-ACTION study19 was categorised as North America, but was also delivered to a small number of patients in France.
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FIGURE 7 Funnel plots for HRQoL and exercise capacity analyses. (a) MLHFQ score (points ) (at 12 months), Egger’s
test –1.40, p= 0.656; (b) all HRQoL measures (at 12 months), Egger’s test –0.72, p= 0.577; (c) VO2peak directly
reported (at 12 months), Egger’s test 0.99, p= 0.665; (d) 6MWT directly reported (at 12 months), Egger’s test 1.71,
p= 0.150; and (e) all exercise capacity measures (at 12 months), Egger’s test 1.85, p= 0.214. (continued )
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One-stage meta-analysis showed a significant improvement in HRQoL as assessed by the MLHFQ (mean
difference –5.94 points, 95% CI –1.0 to –10.9 points; p = 0.018, τ2 = 77, I2 = 88%) and standardised
HRQoL score (mean difference SD 0.20, 95% CI 0.03 to 0.37; p = 0.020, τ2 = 0.07, I2 = 85%), at the
12-month follow-up. Similar results were seen at the 6-month follow-up (Figures 8 and 9). Marked
statistical heterogeneity (I2 > 70%) was seen for all exercise capacity and HRQoL outcomes.
Analyses revealed no consistent interaction between the effect of ExCR and the predefined subgroups
(sex, ejection fraction, NYHA class, HF aetiology, ethnicity and baseline exercise capacity), for either
exercise or HRQoL.
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FIGURE 7 Funnel plots for HRQoL and exercise capacity analyses. (a) MLHFQ score (points ) (at 12 months), Egger’s
test –1.40, p= 0.656; (b) all HRQoL measures (at 12 months), Egger’s test –0.72, p= 0.577; (c) VO2peak directly
reported (at 12 months), Egger’s test 0.99, p= 0.665; (d) 6MWT directly reported (at 12 months), Egger’s test 1.71,
p= 0.150; and (e) all exercise capacity measures (at 12 months), Egger’s test 1.85, p= 0.214.
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TABLE 13 Assessment of quality using TESTEX scale31 of included studies in HRQoL and exercise capacity analysis
First author/study (year)
Eligibility
criteria
specified
Randomisation
specified
Allocation
concealed
Groups
similar at
baseline
Blinding of
assessors
Outcome
measures in
> 85% of
participantsa
Intention-
to-treat
analysisb
Between-
group
statistical
comparisons
reported
Point
measures and
measures of
variability
reported
Activity
monitoring
in control
group
Relative
Exercise
intensity
reviewed
Exercise
volume
and
energy
expended
Overall
TESTEX
score
(maximum
score of 15)
Belardinelli et al. (2012)56 1 0 0 1 0 3 1 1 1 0 0 1 9
Dracup et al. (2007)58 1 0 0 1 0 3 1 2 1 1 1 1 10
Gary et al. (2010)59 1 1 0 1 1 3 1 2 1 0 0 0 11
Giannuzzi et al. (2003)60 1 0 0 1 0 2 1 2 1 0 1 1 10
Hambrecht et al. (2000)51 1 1 0 1 0 3 0 2 1 0 1 1 11
HF-ACTION (2009)19 1 1 1 1 1 3 1 2 1 1 0 1 14
Jolly et al. (2009)61 1 1 1 1 0 2 1 2 1 0 1 1 12
Mueller et al. (2007)62 1 0 0 1 0 2 1 2 1 0 1 1 10
Nilsson et al. (2008)63 1 1 0 1 1 2 1 2 1 0 0 1 11
Passino et al. (2006)67 1 0 0 1 0 2 1 2 1 0 1 1 10
Witham et al. (2005)64 1 1 0 1 1 3 1 2 1 0 1 0 12
Witham et al. (2012)65 1 1 0 1 1 3 1 2 1 0 1 0 12
Yeh et al. (2011)66 1 1 0 1 1 3 1 2 1 1 0 0 12
a Three points possible.
b If intention to treat was not specifically mentioned, but it was noted that no participants withdrew and all were analysed, then 1 point was awarded.
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Overall (I 2 = 5.0%; p = 0.388)
Yeh (2011)66
Witham (2012)65
Nilsson (2008)63
Jolly (2009)61
Gary (2010 – CBT)59
Gary (2010 – usual care)59
Dracup (2007)58
– 1.72 (– 4.15 to 0.70)
– 3.09 (– 9.31 to 3.14)
0.85 (– 3.13 to 4.83)
– 6.78 (– 13.05 to – 0.50)
0.25 (– 4.99 to 5.49)
– 9.54 (– 22.37 to 3.29)
– 3.51 (– 17.28 to 10.27)
– 1.66 (– 8.37 to 5.04)
100.00
14.36
32.60
14.15
19.83
3.53
3.06
12.47
– 20 0 20
First author/study (year)
(a)
Effect (95% CI) Weight (%)
Overall (I 2 = 0.0%; p = 0.567)
Yeh (2011)66
Witham (2012)65
Witham (2005)64
Nilsson (2008)63
Jolly (2009)61
HF-ACTION (2009)19
Gary (2010 – CBT)59
Gary (2010 – usual care)59
Dracup (2007)58
– 0.10 (– 0.15 to – 0.05)
– 0.16 (– 0.44 to 0.12)
0.04 (– 0.16 to 0.24)
0.04 (– 0.40 to 0.49)
– 0.30 (– 0.57 to – 0.02)
0.01 (– 0.22 to 0.24)
– 0.11 (– 0.17 to – 0.05)
– 0.41 (– 0.97 to 0.15)
– 0.16 (– 0.75 to 0.43)
– 0.10 (– 0.39 to 0.19)
100.00
3.53
6.90
1.38
3.59
5.14
74.67
0.86
0.77
3.16
– 1 0 1
First author/study (year)
(b)
Effect (95% CI) Weight (%)
Overall (I 2 = 80.4%; p = 0.000)
Yeh (2011)66
Passino (2006)67
Mueller (2007)62
HF-ACTION (2009)19
Hambrecht (2000)51
Dracup (2007)58
0.69 (– 0.24 to 1.62)
– 0.02 (– 1.02 to 0.98)
1.57 (0.66 to 2.49)
4.48 (2.35 to 6.60)
0.47 (0.24 to 0.71)
– 2.16 (– 4.43 to 0.10)
0.04 (– 1.26 to 1.34)
100.00
19.02
19.72
10.74
24.03
9.98
16.52
– 5 0 5
First author/study (year)
(c)
Effect (95% CI) Weight (%)
FIGURE 8 Effect of ExCR on HRQoL and exercise capacity at 6 months: two-stage IPD meta-analysis. (a) MLHFQ
score (points) (mean difference); (b) all HRQoL measures (standardised mean difference); (c) VO2peak directly
reported (mean difference); (d) 6MWT (m) directly reported (mean difference); and (e) all exercise capacity
measures (standardised mean difference). Note that weights are from random effects, DerSimonian–Laird
estimator. CBT, cognitive–behavioural therapy. (continued )
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Overall (I 2 = 76.9%; p = 0.000)
Yeh (2011)66
Witham (2012)65
Witham (2005)64
Nilsson (2008)63
HF-ACTION (2009)19
Gary (2010 – CBT)59
Gary (2010 – usual care)59
Dracup (2007)58
24.35 (6.13 to 42.57)
1.25 (– 24.71 to 27.20)
– 2.03 (– 26.14 to 22.07)
5.18 (– 17.41 to 27.76)
77.22 (47.58 to 106.87)
18.14 (11.60 to 24.68)
91.74 (41.52 to 141.96)
42.79 (– 15.06 to 100.64)
5.19 (– 28.39 to 38.78)
100.00
13.75
14.30
14.75
12.68
18.62
7.79
6.53
11.58
– 100 0 100
First author/study (year)
(d)
Effect (95% CI) Weight (%)
First author/study (year)
(e)
Overall (I 2 = 85.3%; p = 0.000)
Yeh (2011)66
Witham (2012)65
Witham (2005)64
Passino (2006)67
Nilsson (2008)63
Mueller (2007)62
Jolly (2009)61
HF-ACTION (2009)19
Hambrecht (2000)51
Giannuzzi (2003)60
Gary (2010 – CBT)59
Gary (2010 – usual care)59
Dracup (2007)58
Effect (95% CI)
0.26 (0.12 to 0.40)
0.00 (– 0.20 to 0.21)
– 0.04 (– 0.22 to 0.14)
0.10 (– 0.09 to 0.28)
0.32 (0.13 to 0.51)
0.53 (0.33 to 0.73)
0.86 (0.45 to 1.27)
0.16 (– 0.04 to 0.37)
0.09 (0.04 to 0.14)
– 0.39 (– 0.80 to 0.02)
0.77 (0.52 to 1.01)
0.65 (0.30 to 0.99)
0.32 (– 0.09 to 0.72)
0.15 (– 0.09 to 0.38)
Weight (%)
100.00
8.41
8.79
8.62
8.67
8.43
5.45
8.35
10.11
5.47
7.85
6.35
5.54
7.99
– 1 0 1
FIGURE 8 Effect of ExCR on HRQoL and exercise capacity at 6 months: two-stage IPD meta-analysis. (a) MLHFQ
score (points) (mean difference); (b) all HRQoL measures (standardised mean difference); (c) VO2peak directly
reported (mean difference); (d) 6MWT (m) directly reported (mean difference); and (e) all exercise capacity
measures (standardised mean difference). Note that weights are from random effects, DerSimonian–Laird
estimator. CBT, cognitive–behavioural therapy.
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Overall (I 2 = 88.1%; p = 0.000)
Yeh (2011)66
Witham (2012)65
Passino (2006)67
Nilsson (2008)63
Jolly (2009)61
Gary (2010 – CBT)59
Gary (2010 – usual care)59
Dracup (2007)58
– 5.73 (– 12.38 to 0.92)
– 3.09 (– 9.31 to 3.14)
0.85 (– 3.13 to 4.83)
– 23.40 (– 28.87 to – 17.94)
– 6.78 (– 13.05 to – 0.50)
1.35 (– 4.02 to 6.71)
– 9.54 (– 22.37 to 3.29)
– 3.51 (– 17.28 to 10.27)
– 2.19 (– 9.09 to 4.70)
100.00
13.30
14.29
13.67
13.28
13.71
9.65
9.15
12.96
– 20 0 20
First author/study (year)
(a)
Effect (95% CI) Weight (%)
Overall (I 2 = 84.7%; p = 0.000)
Yeh (2011)66
Witham (2012)65
Witham (2005)64
Passino (2006)67
Nilsson (2008)63
Jolly (2009)61
HF-ACTION (2009)19
Gary (2010 – CBT)59
Gary (2010 – usual care)59
Dracup (2007)58
– 0.19 (– 0.38 to – 0.01)
– 0.16 (– 0.44 to 0.12)
0.04 (– 0.16 to 0.24)
0.04 (– 0.40 to 0.49)
– 0.82 (– 1.01 to – 0.63)
– 0.30 (– 0.57 to – 0.02)
0.07 (– 0.16 to 0.30)
– 0.10 (– 0.17 to – 0.04)
– 0.41 (– 0.97 to 0.15)
– 0.16 (– 0.75 to 0.43)
– 0.14 (– 0.43 to 0.16)
100.00
10.57
11.91
7.78
12.01
10.61
11.38
13.51
6.18
5.78
10.26
– 1 0 1
First author/study (year)
(b)
Effect (95% CI) Weight (%)
Overall (I 2 = 93.8%; p = 0.000)
Yeh (2011)66
Passino (2006)67
Mueller (2007)62
HF-ACTION (2009)19
Hambrecht (2000)51
Dracup (2007)58
Belardinelli (2012)56
1.14 (– 0.05 to 2.34)
– 0.02 (– 1.02 to 0.98)
2.75 (1.66 to 3.85)
4.48 (2.35 to 6.60)
0.51 (0.25 to 0.76)
– 2.16 (– 4.43 to 0.10)
– 0.49 (– 1.74 to 0.75)
2.71 (2.21 to 3.21)
100.00
15.28
14.97
11.10
16.99
10.59
14.43
16.63
– 5 0 5
First author/study (year)
(c)
Effect (95% CI) Weight (%)
FIGURE 9 Effect of ExCR on HRQoL and exercise capacity at 12 months: two-stage IPD meta-analysis. (a) MLHFQ
score (points) (mean difference); (b) all HRQoL measures (standardised mean difference); (c) VO2peak directly
reported (mean difference); (d) 6MWT (m) directly reported (mean difference); and (e) all exercise capacity
measures (standardised mean difference). Note that weights are from random effects, DerSimonian–Laird
estimator. CBT, cognitive–behavioural therapy. (continued )
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Overall (I 2 = 78.3%; p = 0.000)
Yeh (2011)66
Witham (2012)65
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Nilsson (2008)63
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Gary (2010 – CBT)59
Gary (2010 – usual care)59
Dracup (2007)58
23.98 (5.30 to 42.65)
1.25 (– 24.71 to 27.20)
– 2.03 (– 26.14 to 22.07)
5.18 (– 17.41 to 27.76)
77.22 (47.58 to 106.87)
9.24 (1.99 to 16.48)
91.74 (41.52 to 141.96)
42.79 (– 15.06 to 100.64)
14.62 (– 15.31 to 44.55)
100.00
13.62
14.13
14.55
12.61
17.98
7.91
6.66
12.53
– 100 0 100
First author/study (year)
(d)
Effect (95% CI) Weight (%)
Overall (I 2 = 90.9%; p = 0.000)
Yeh (2011)66
Witham (2012)65
Witham (2005)64
Passino (2006)67
Nilsson (2008)63
Mueller (2007)62
Jolly (2009)61
HF-ACTION (2009)19
Hambrecht (2000)51
Giannuzzi (2003)60
Gary (2010 – CBT)59
Gary (2010 – usual care)59
Dracup (2007)58
Belardinelli (2012)56
0.30 (0.14 to 0.46)
0.00 (– 0.20 to 0.21)
– 0.04 (– 0.22 to 0.14)
0.10 (– 0.09 to 0.28)
0.55 (0.33 to 0.77)
0.53 (0.33 to 0.73)
0.86 (0.45 to 1.27)
0.16 (– 0.04 to 0.37)
0.08 (0.02 to 0.13)
– 0.39 (– 0.80 to 0.02)
0.77 (0.52 to 1.01)
0.65 (0.30 to 0.99)
0.32 (– 0.09 to 0.72)
0.16 (– 0.12 to 0.44)
0.55 (0.45 to 0.65)
100.00
7.62
7.86
7.76
7.48
7.64
5.53
7.59
8.62
5.54
7.26
6.21
5.60
6.88
8.41
– 1 0 1
First author/study (year)
(e)
Effect (95% CI) Weight (%)
FIGURE 9 Effect of ExCR on HRQoL and exercise capacity at 12 months: two-stage IPD meta-analysis. (a) MLHFQ
score (points) (mean difference); (b) all HRQoL measures (standardised mean difference); (c) VO2peak directly
reported (mean difference); (d) 6MWT (m) directly reported (mean difference); and (e) all exercise capacity
measures (standardised mean difference). Note that weights are from random effects, DerSimonian–Laird
estimator. CBT, cognitive–behavioural therapy.
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A differential effect of ExCR across ages was observed in the standardised HRQoL analysis, with a reduction
in HRQoL score (i.e. an increase in standardised HRQoL score) as age increased (SD 0.006, 95% 0.002 to
0.011; p = 0.006). To put this into context, based on a MLHFQ SD of 24 points, this equates to a decrease
of 1.4 points in the treatment effect on the MLHFQ score for every 10-year increase in patient age.
Interaction analyses for the one-stage model at the 12-month follow-up showed differential effects of
ExCR by sex, with women showing greater benefit than men for VO2peak (0.57 ml/kg/minute, 95% CI
0.04 to 1.11 ml/kg/minute; p = 0.036) and the 6MWT (14.9 m, 95% CI 1.2 to 28.7 m; p = 0.034).
Differential effects of ExCR were also seen between ethnic groups, with white patients showing a greater
improvement in 6MWT distance than non-white patients (14.2 m, 95% CI 0.40 to 28.0 m; p = 0.044).
Secondary analysis
In the repeated measures analyses for each HRQoL and exercise capacity outcome, a significant interaction
between ExCR and time was observed (Figure 10). To visualise comparisons of changes in HRQoL and
exercise capacity in each subgroup, the effect estimates and associated 95% CI from individual subgroup
one-stage IPD meta-analyses are shown in Figure 11. The p-values from the interaction test in the two-stage
IPD meta-analyses are presented alongside these estimates.
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FIGURE 10 Effect of ExCR on HRQoL and exercise capacity. (a) MLHFQ score (points) (mean difference); (b) all HRQoL
measures (standardised mean difference); (c) VO2peak directly reported (mean difference); (d) 6MWT directly
reported (mean difference); and (e) all exercise capacity measures (standardised mean difference). (continued )
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measures (standardised mean difference); (c) VO2peak directly reported (mean difference); (d) 6MWT directly
reported (mean difference); and (e) all exercise capacity measures (standardised mean difference).
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Age (years)
< 60
≥ 60
Sex
Male
Female
Ejection fraction (%)
HFrEF
HFpEF
NYHA class
I/II
III/IV
HF aetiology
Ischaemic
Non-ischaemic
Ethnic group
White
Non-white
VO2peak (ml/kg/minute)
< 15
≥ 15
Overall
– 7.76 (– 13.7 to – 1.88)
– 5.02 (– 10.8 to 0.75)
 
– 7.42 (13.6 to – 1.27)
– 3.44 (– 8.10 to 1.22)
 
– 6.48 (– 13.3 to 0.32)
– 6.07 (– 15.0 to 2.89)
 
– 3.95 (– 8.67 to 0.77)
– 10.2 (– 16.7 to – 3.68)
 
– 5.50 (– 11.7 to 0.74)
– 7.04 (– 13.7 to – 0.37)
 
– 5.68 (– 11.1 to – 0.24)
– 5.29 (– 13.1 to 2.47)
 
– 12.1 (– 24.2 to 0.12)
– 3.29 (– 6.96 to 0.38)
 
0.912
 
0.592
 
0.165
 
0.061
 
0.477
 
0.169
 
0.262
Coefficient (95% CI)
(a)
p-value for interactiona
– 5.94 (– 10.9 to – 1.01)
0 5– 5– 10– 15– 20
Age (years)
< 60
≥ 60
Sex
Male
Female
Ejection fraction (%)
HFrEF
HFpEF
NYHA class
I/II
III/IV
HF aetiology
Ischaemic
Non-ischaemic
Ethnic group
White
Non-white
VO2peak (ml/kg/minute)
< 15
≥ 15
Overall
 
– 0.16 (– 0.25 to – 0.08)
– 0.17 (– 0.35 to 0.01)
 
– 0.27 (– 0.47 to – 0.07)
– 0.13 (– 0.23 to – 0.02)
 
– 0.24 (– 0.48 to – 0.01)
– 0.23 (– 0.54 to 0.07)
 
– 0.18 (– 0.33 to – 0.02)
– 0.23 (– 0.04 to – 0.01)
 
– 0.19 (– 0.41 to 0.02)
– 0.30 (– 0.52 to – 0.08)
 
– 0.18 (– 0.36 to – 0.01)
– 0.12 (– 0.22 to – 0.01)
 
– 0.48 (– 0.88 to – 0.08)
– 0.10 (– 0.23 to 0.02)
 
0.734
 
0.775
 
0.340
 
0.505
 
0.611
 
0.787
 
0.230
Coefficient (95% CI)
(b)
p-value for interactiona
– 0.20 (– 0.37 to – 0.03)
0– 0.2– 0.4– 0.6– 0.8
FIGURE 11 Effect of ExCR on HRQoL and exercise capacity across patient subgroups (individual subgroup one-stage
IPD meta-analyses). (a) MLHFQ score (points); (b) all HRQoL measures (standardised score); (c) VO2peak directly
reported; (d) 6MWT (m) directly reported; and (e) all exercise capacity measures (standardised score). a, Although
stratified meta-analyses are shown, the interaction p-values are calculated based on continuous distribution of age,
ejection fraction and baseline exercise capacity. (continued )
IMPACT ON HEALTH-RELATED QUALITY OF LIFE AND EXERCISE CAPACITY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
46
Age (years)
< 60
≥ 60
Sex
Male
Female
Ejection fraction (%)
HFrEF
HFpEF
NYHA class
I/II
III/IV
HF aetiology
Ischaemic
Non-ischaemic
Ethnic group
White
Non-white
VO2peak (ml/kg/minute)
< 15
≥ 15
Overall
 
1.12 (– 0.31 to 2.56)
0.90 (– 0.47 to 2.28)
 
0.92 (– 0.59 to 2.42)
0.99 (0.59 to 1.39)
 
1.15 (– 0.49 to 2.79)
1.22 (– 0.10 to 2.54)
 
0.78 (– 0.63 to 2.18)
0.38 (– 0.32 to 1.08)
 
1.20 (– 0.55 to 2.96)
0.77 (– 0.57 to 2.11)
 
1.30 (– 0.32 to 2.92)
0.47 (0.08 to 0.86)
 
1.12 (0.14 to 2.10)
0.88 (– 0.72 to 2.47)
 
0.646
 
0.036
 
0.897
 
0.318
 
0.577
 
0.800
 
0.332
Coefficient (95% CI)
(c)
p-value for interactiona
1.01 (– 0.42 to 2.44)
0 1 2
Age (years)
< 60
≥ 60
Sex
Male
Female
Ejection fraction (%)
HFrEF
HFpEF
NYHA class
I/II
III/IV
HF aetiology
Ischaemic
Non-ischaemic
Ethnic group
White
Non-white
6 MWT at baseline
< 360 m
≥ 360 m
Overall
 
11.9 (1.98 to 21.9)
21.0 (1.36 to 40.6)
 
11.1 (– 12.6 to 34.7)
23.4 (12.4 to 34.4)
 
22.0 (0.04 to 43.9)
59.1 (20.3 to 98.9)
 
21.5 (– 2.21 to 45.1)
14.6 (3.74 to 25.5)
 
21.6 (– 1.73 to 45.0)
6.60 (– 21.0 to 34.2)
 
22.1 (3.35 to 40.8)
1.43 (– 9.83 to 12.7)
 
16.2 (6.54 to 25.8)
12.0 (– 13.4 to 37.5)
 
0.911
 
0.034
 
0.560
 
0.847
 
0.510
 
0.044
 
0.176
Coefficient (95% CI)
(d)
p-value for interactiona
21.0 (1.57 to 40.4)
0 20 40 60 80
FIGURE 11 Effect of ExCR on HRQoL and exercise capacity across patient subgroups (individual subgroup one-stage
IPD meta-analyses). (a) MLHFQ score (points); (b) all HRQoL measures (standardised score); (c) VO2peak directly
reported; (d) 6MWT (m) directly reported; and (e) all exercise capacity measures (standardised score). a, Although
stratified meta-analyses are shown, the interaction p-values are calculated based on continuous distribution of age,
ejection fraction and baseline exercise capacity. (continued )
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Sensitivity analyses
In sensitivity analyses, the results of the analyses excluding HF-ACTION,19 were broadly consistent with the
overall results (Tables 14–18). Similar results were found with the addition of the study-level aggregate
data to the two-stage model at 12 months’ follow-up.
0 0.2 0.6
Age (years)
< 60
≥ 60
Sex
Male
Female
Ejection fraction (%)
HFrEF
HFpEF
NYHA class
I/II
III/IV
HF aetiology
Ischaemic
Non-ischaemic
Ethnic group
White
Non-white
Standardised exercise capacity score
< 0
≥ 0
Overall
 
0.31 (0.11 to 0.51)
0.25 (0.12 to 0.38)
 
0.24 (0.05 to 0.42)
0.28 (0.16 to 0.39)
 
0.31 (0.12 to 0.50)
0.41 (0.17 to 0.64)
 
0.25 (0.08 to 0.41)
0.20 (0.08 to 0.32)
 
0.30 (0.15 to 0.45)
0.19 (0.00 to 0.39)
 
0.29 (0.14 to 0.45)
0.07 (– 0.02 to 0.15)
 
0.28 (0.16 to 0.39)
0.23 (0.02 to 0.43)
 
0.636
 
0.065
 
0.733
 
0.377
 
0.620
 
0.741
 
0.105
Coefficient (95% CI)
(e)
p-value for interactiona
0.27 (0.11 to 0.43)
FIGURE 11 Effect of ExCR on HRQoL and exercise capacity across patient subgroups (individual subgroup one-stage
IPD meta-analyses). (a) MLHFQ score (points); (b) all HRQoL measures (standardised score); (c) VO2peak directly
reported; (d) 6MWT (m) directly reported; and (e) all exercise capacity measures (standardised score). a, Although
stratified meta-analyses are shown, the interaction p-values are calculated based on continuous distribution of age,
ejection fraction and baseline exercise capacity.
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TABLE 14 Minnesota Living with Heart Failure: overall treatment effect and subgroup (interaction) effects
Baseline variable
Primary analyses, mean difference (95% CI); p-value Sensitivity analyses excluding HF-ACTION,19 mean difference (95% CI); p-value
One-stage model,
6-month follow-up,
with random
treatment effect
Two-stage model,
6-month follow-up,
with random
treatment effect
One-stage model,
12-month follow-up,
with random
treatment effect
Two-stage model,
12-month follow-up,
with random
treatment effect
One-stage model,
6-month follow-up,
with random
treatment effect
Two-stage model,
6-month follow-up,
with random
treatment effect
One-stage model,
12-month follow-up,
with random
treatment effect
Two-stage model,
12-month follow-up,
with random
treatment effect
Overall effect –2.85 (–5.85 to 0.14);
0.062
–1.73 (–4.15 to 0.70);
0.163
–5.94 (–10.87 to –1.01);
0.018
–5.73 (–12.38 to 0.93);
0.091
Not applicable to MLHFQ analyses as HF-ACTION19 only supplied KCCQ scores
Interaction term
Age (years) 0.12 (–0.10 to 0.35);
0.280
0.01 (–0.20 to 0.22);
0.912
Gender
(male vs. female)
–5.31 (–11.01 to 0.39);
0.068
–1.49 (–6.95 to 3.96);
0.592
Ejection fraction (%) 0.22 (–0.14 to 0.58);
0.227
0.24 (–0.07 to 0.56);
0.127
Ejection fraction
(HFrEF vs. HFpEF)
4.06 (–11.0 to 19.1);
0.597
8.02 (–3.29 to 19.3);
0.165
NYHA class
(NYHA I/II vs.
NYHA III/IV)
–6.38 (–12.31 to –0.45);
0.035
–5.30 (–10.9 to 0.24);
0.061
HF aetiology
(ischaemic vs.
non-ischaemic)
4.67 (–1.65 to 11.0);
0.147
2.08 (–3.64 to 7.80);
0.477
Ethnic group
(white vs. non-white)
3.15 (–4.31 to 10.6);
0.408
5.17 (–2.19 to 12.5);
0.169
Exercise capacity
Baseline VO2peak
directly measured
0.24 (–0.82 to 1.31);
0.654
0.47 (–0.35 to 1.29);
0.262
Baseline VO2peak
directly measured
and predicted
0.72 (–0.01 to 1.45);
0.053
0.62 (–0.02 to 1.26);
0.058
KCCQ, Kansas City Cardiomyopathy Questionnaire.
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TABLE 15 Standardised HRQoL measure: overall treatment effect and subgroup (interaction) effects
Baseline variable
Primary analyses, mean difference (95% CI); p-value Sensitivity analyses excluding HF-ACTION,19 mean difference (95% CI); p-value
One-stage model,
6-month follow-up,
with random
treatment effect
Two-stage model,
6-month follow-up,
with random
treatment effect
One-stage model,
12-month follow-up,
with random
treatment effect
Two-stage model,
12-month follow-up,
with random
treatment effect
One-stage model,
6-month follow-up,
with random
treatment effect
Two-stage model,
6-month follow-up,
with random
treatment effect
One-stage model,
12-month follow-up,
with random
treatment effect
Two-stage model,
12-month follow-up,
with random
treatment effect
Overall effect –0.11 (–0.16 to –0.06);
< 0.001
–0.10 (–0.15 to –0.05);
< 0.001
–0.20 (–0.37 to –0.03);
0.020
–0.19 (–0.38 to –0.01);
0.043
–0.11 (–0.24 to 0.01);
0.069
–0.08 (–0.18 to 0.02);
0.131
–0.17 (–0.28 to –0.07);
0.001a
–0.21 (–0.45 to 0.04);
0.106
Interaction terms
Age (years) 0.006 (0.002 to 0.011);
0.006
0.001 (–0.004 to 0.005);
0.734
0.003 (–0.007 to 0.014);
0.536
–0.001 (–0.011 to 0.008);
0.788
Gender
(male vs. female)
0.050 (–0.068 to 0.168);
0.407
0.018 (–0.105 to 0.140);
0.775
–0.223 (–0.469 to 0.024);
0.077
–0.106 (–0.335 to 0.123);
0.365
Ejection fraction (%) –0.000 (–0.007 to 0.007);
0.963
–0.004 (–0.011 to 0.004);
0.340
0.010 (–0.006 to 0.025);
0.225
0.010 (–0.003 to 0.023);
0.150
Ejection fraction (%)
(HFrEF vs. HFpEF)
–0.03 (–0.46 to 0.41);
0.902
0.13 (–0.26 to 0.53);
0.505
0.16 (–0.47 to 0.84);
0.581
0.34 (–0.14 to 0.81);
0.163
NYHA class
(NYHA I/II vs.
NYHA III/IV)
–0.013 (–0.126 to 0.100);
0.824
0.031 (–0.086 to 0.149);
0.599
–0.126 (–0.380 to 0.129);
0.334
–0.082 (–0.314 to 0.151);
0.491
HF aetiology
(ischaemic vs.
non-ischaemic)
0.076 (–0.036 to 0.187);
0.182
0.030 (–0.085 to 0.145);
0.611
0.220 (–0.055 to 0.494);
0.117
0.080 (–0.162 to 0.322);
0.517
Ethnic group
(white vs. non-white)
0.041 (–0.079 to 0.161);
0.506
0.017 (–0.108 to 0.142);
0.787
0.173 (–0.172 to 0.519);
0.325
0.243 (–0.086 to 0.573);
0.147
Exercise capacity
Baseline VO2peak
directly measured
–0.002 (–0.014 to –0.011);
0.775
0.008 (–0.005 to 0.021);
0.230
0.012 (–0.035 to 0.059);
0.612
0.021 (–0.012 to 0.055);
0.216
Baseline VO2peak
directly measured
and predicted
0.000 (–0.012 to 0.013);
0.956
0.008 (–0.004 to 0.021);
0.208
0.023 (–0.010 to 0.056);
0.171
0.020 (–0.008 to 0.048);
0.172
a Fixed effect on treatment with a random effect on study, due to non-convergence of the random treatment effect model.
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TABLE 16 Peak oxygen uptake directly measured: overall treatment effect and subgroup (interaction) effects
Baseline variable
Primary analyses, mean difference (95% CI); p-value Sensitivity analyses excluding HF-ACTION,19 mean difference (95% CI); p-value
One-stage model,
6-month follow-up,
with random
treatment effect
Two-stage model,
6-month follow-up,
with random
treatment effect
One-stage model,
12-month follow-up,
with random
treatment effect
Two-stage model,
12-month follow-up,
with random
treatment effect
One-stage model,
6-month follow-up,
with random
treatment effect
Two-stage model,
6-month follow-up,
with random
treatment effect
One-stage model,
12-month follow-up,
with random
treatment effect
Two-stage model,
12-month follow-up,
with random
treatment effect
Overall effect 0.62 (–0.82 to 2.07);
0.397
0.69 (–0.24 to 1.62);
0.145
1.01 (–0.42 to 2.44);
0.168
1.14 (–0.05 to 2.34);
0.061
0.71 (–1.10 to 2.52);
0.444
0.77 (–0.73 to 2.28);
0.315
1.15 (–0.60 to 2.90);
0.196
1.26 (–0.31 to 2.82);
0.115
Interactions term
Age (years) 0.00 (–0.02 to 0.02);
0.980
–0.00 (–0.02 to 0.14);
0.646
–0.01 (–0.07 to 0.04);
0.628
–0.02 (–0.06 to 0.03);
0.415
Gender
(male vs. female)
–0.25 (–0.78 to 0.27);
0.345
–0.57 (–1.11 to –0.04);
0.036
–0.67 (–2.47 to 1.14);
0.468
–0.42 (–1.80 to 0.95);
0.549
Ejection fraction (%) 0.03 (0.00 to 0.06);
0.034
0.02 (–0.01 to 0.05);
0.157
0.05 (–0.04 to 0.13);
0.280
0.03 (–0.04 to 0.11);
0.349
Ejection fraction (%)
(HFrEF vs. HFpEF)
0.07 (–1.88 to 2.01);
0.947
–0.13 (–2.07 to 1.81);
0.897
–1.34 (–2.42 to 5.09);
0.485
–0.19 (–3.34 to 2.97);
0.907
NYHA class
(NYHA I/II vs.
NYHA III/IV)
–0.10 (–0.58 to 0.38);
0.687
–0.25 (–0.75 to 0.24);
0.318
–0.50 (–2.13 to 1.13);
0.549
–0.75 (–1.95 to 0.46);
0.224
HF aetiology
(ischaemic vs.
non-ischaemic)
0.02 (–0.44 to 0.47);
0.945
–0.13 (–0.60 to 0.34);
0.577
–0.63 (–2.04 to 0.79);
0.386
–0.24 (–1.39 to 0.91);
0.683
Ethnic group
(white vs. non-white)
–0.19 (–0.66 to 0.29);
0.447
–0.07 (–0.58 to 0.45);
0.800
–0.47 (–2.36 to 1.43);
0.628
0.16 (–1.71 to 2.03);
0.870
Exercise capacity
Baseline VO2peak
directly measured
0.01 (–0.04 to 0.06);
0.719
0.03 (–0.03 to 0.08);
0.332
–0.06 (–0.21 to 0.09);
0.435
–0.04 (–0.17 to 0.10);
0.602
Baseline VO2peak
directly measured
and predicted
0.01 (–0.04 to 0.06);
0.702
0.03 (–0.02 to 0.08);
0.299
–0.06 (–0.21 to 0.09);
0.452
–0.03 (–0.16 to 0.10);
0.660
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TABLE 17 Six-minute walk test directly measured: overall treatment effect and subgroup (interaction) effects
Baseline variable
Primary analyses, mean difference (95% CI); p-value Sensitivity analyses excluding HF-ACTION,19 mean difference (95% CI); p-value
One-stage model,
6-month follow-up,
with random
treatment effect
Two-stage model,
6-month follow-up,
with random
treatment effect
One-stage model,
12-month follow-up,
with random
treatment effect
Two-stage model,
12-month follow-up,
with random
treatment effect
One-stage model,
6-month follow-up,
with random
treatment effect
Two-stage model,
6-month follow-up,
with random
treatment effect
One-stage model,
12-month follow-up,
with random
treatment effect
Two-stage model,
12-month follow-up,
with random
treatment effect
Overall effect 22.1 (1.87 to 42.3);
0.032
24.4 (6.13 to 42.6);
0.009
21.0 (1.57 to 40.4);
0.034
24.0 (5.30 to 42.7);
0.012
22.1 (–1.64 to 45.8);
0.068
27.9 (1.25 to 54.6);
0.040
24.0 (1.25 to 46.7);
0.039
29.0 (3.05 to 55.0);
0.029
Interaction terms
Age (years) 0.01 (–0.49 to 0.50);
0.973
–0.03 (–0.56 to 0.50);
0.911
0.45 (–0.81 to 1.72);
0.482
0.97 (–0.23 to 2.17);
0.115
Gender
(male vs. female)
–10.7 (–23.6 to 2.26);
0.106
–14.9 (–28.7 to –1.16);
0.034
–19.7 (–47.3 to 7.92);
0.162
–13.5 (–39.9 to 12.9);
0.317
Ejection fraction (%) 0.34 (–0.46 to 1.14);
0.399
0.21 (–0.64 to 1.06);
0.634
1.05 (–0.78 to 2.88);
0.262
0.04 (–1.69 to 1.77);
0.963
Ejection fraction (%)
(HFrEF vs. HFpEF)
0.68 (–47.8 to 49.2);
0.978
15.4 (–36.3 to 67.0);
0.560
13.8 (–6.09 to 88.6);
0.717
14.7 (–56.1 to 85.4);
0.685
NYHA class
(NYHA I/II vs.
NYHA III/IV)
–1.81 (–14.3 to 10.6);
0.776
1.31 (–12.0 to 14.6);
0.847
–5.90 (–34.6 to 22.8);
0.687
–8.14 (–35.7 to 19.4);
0.563
HF aetiology
(ischaemic vs.
non-ischaemic)
3.73 (–8.26 to 15.7);
0.542
–4.30 (–17.1 to 8.51);
0.510
37.9 (9.34 to 66.4);
0.009
26.9 (–0.13 to 54.0);
0.051
Ethnic group
(white vs. non-white)
10.46 (–2.55 to 23.5);
0.115
14.2 (0.40 to 28.0);
0.044
–20.7 (–60.5 to 19.0);
0.307
8.34 (–29.5 to 46.1);
0.665
Exercise capacity
Baseline 6MWT
directly measured
–0.05 (–0.11 to 0.01);
0.079
0.19 (–0.08 to 0.46);
0.176
–0.06 (–0.18 to 0.06);
0.321
–0.05 (–0.16 to 0.07);
0.421
IM
PA
CT
O
N
H
EA
LTH
-RELA
TED
Q
U
A
LITY
O
F
LIFE
A
N
D
EXERCISE
CA
PA
CITY
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
52
TABLE 18 Standardised exercise capacity score: overall treatment effect and subgroup (interaction) effects
Baseline variable
Primary analyses, mean difference (95% CI); p-value Sensitivity analyses excluding HF-ACTION,19 mean difference (95% CI); p-value
One-stage model,
6-month follow-up,
with random
treatment effect
Two-stage model,
6-month follow-up,
with random
treatment effect
One-stage model,
12-month follow-up,
with random
treatment effect
Two-stage model,
12-month follow-up,
with random
treatment effect
One-stage model,
6-month follow-up,
with random
treatment effect
Two-stage model,
6-month follow-up,
with random
treatment effect
One-stage model,
12-month follow-up,
with random
treatment effect
Two-stage model,
12-month follow-up,
with random
treatment effect
Overall effect 0.230 (0.067 to 0.392);
0.006
0.256 (0.116 to 0.396);
<0.001
0.268 (0.110 to 0.426);
0.001
0.302 (0.142 to 0.462);
< 0.001
0.256 (0.079 to 0.433);
0.005
0.278 (0.105 to 0.451);
0.002
0.298 (0.125 to 0.471);
0.001
0.324 (0.150 to 0.497);
<0.001
Interaction terms
Age (years) 0.001 (–0.003 to 0.004);
0.758
–0.001 (–0.005 to 0.003);
0.636
0.003 (–0.008 to 0.014);
0.565
–0.000 (–0.010 to 0.009);
0.948
Gender
(male vs. female)
–0.063 (–0.157 to 0.319);
0.194
–0.096 (–0.197 to 0.006);
0.065
–0.066 (–0.250 to 0.118);
0.484
–0.065 (–0.240 to 0.110);
0.464
Ejection fraction (%) 0.007 (0.001 to 0.012);
0.021
0.005 (–0.001 to 0.011);
0.108
0.008 (–0.003 to 0.019);
0.131
0.008 (–0.003 to 0.018);
0.169
Ejection fraction
(HFrEF vs. HFpEF)
0.11 (–0.20 to 0.43);
0.487
0.06 (–0.28 to 0.40);
0.733
0.21 (–0.23 to 0.65);
0.348
0.06 (–0.36 to 0.49);
0.766
NYHA class
(NYHA I/II vs.
NYHA III/IV)
–0.010 (–0.098 to 0.079);
0.826
–0.043 (–0.138 to 0.052);
0.377
–0.011 (–0.184 to 0.162);
0.900
–0.061 (–0.224 to 0.101);
0.459
HF aetiology
(ischaemic vs.
non-ischaemic)
0.012 (–0.074 to 0.098);
0.783
0.024 (–0.070 to 0.117);
0.620
0.035 (–0.143 to 0.213);
0.701
0.049 (–0.121 to 0.219);
0.573
Ethnic group
(white vs. non-white)
–0.064 (–0.159 to 0.031);
0.187
0.018 (–0.088 to 0.124);
0.741
–0.096 (–0.352 to 0.160);
0.461
0.078 (–0.195 to 0.351);
0.577
Exercise capacity
Standardised scores
using baseline
VO2peak, 6MWT,
ISWT units and
watts score
–0.025 (–0.066 to 0.017);
0.240
–0.017 (–0.048 to 0.508);
0.105
–0.070 (–0.147 to 0.007);
0.077
–0.052 (–0.129 to 0.026);
0.191
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Chapter 7 Results from the surrogate analyses
Inclusion of trials in the ExTraMATCH II surrogate analyses
All 19 trials from the ExTraMATCH II study were eligible for inclusion in the surrogate analyses, if they
provided the required data (as detailed in Chapter 3). Only 10 trials19,51,58,61–67 provided data for the
surrogate analyses. Figure 12 summarises the availability of studies and patient data for exercise capacity
and the patient-relevant outcomes of mortality, hospitalisation and HRQoL.
Characteristics of included patients and trials
Patient baseline characteristics were well balanced across the ExCR and control groups (Table 19). Patients had
a mean age of 62 years and the majority were male (73%). The mean baseline left ventricular ejection fraction
was 26% and most patients were in NYHA functional class II (63%) or III (34%). Studies were published
between 2000 and 2012 from a range of geographical locations (Table 20). Sample size was typically small and
ranged from 50 to 2130 patients. All trials included ExCR based on an aerobic exercise intervention. The dose
of ExCR ranged widely across studies, with an average session duration of 15–60 minutes, of two to seven
sessions per week, exercise intensity equivalent of 40–70% VO2peak and delivery duration of 4–120 weeks.
The change in exercise capacity and final patient-relevant outcomes for each included study are shown
in Table 21.
Assessment of study quality and risk of bias
The overall quality of included trials was judged to be moderate to good, with a median TESTEX31 score of
11 (range 10–14) out of a maximum score of 15 (Table 22).
Findings
Mediation analysis
The four criteria that must be satisfied to establish that change in exercise capacity is a mediator of
mortality, hospitalisation and change in HRQoL are listed in Table 23. First, mean improvements were seen
in all exercise capacity metrics of ExCR compared with control, although none reached statistical significance
at p < 0.05. Second, greater differences in exercise capacity significantly reduced the risk of mortality and
hospitalisation and were associated with a larger gain in HRQoL. Third, although ExCR decreased both the
risk of mortality and hospitalisation, and was also associated with a larger gain in HRQoL, there was no
statistically significant difference compared with the control. Finally, the effect of ExCR compared with
control on final patient-relevant outcomes was attenuated by adding Δ6MWT and ΔVO2peak (directly and
indirectly measured) to the model. No attenuation was seen with the addition of ΔVO2peak when measured
directly.
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ExTraMATCH II IPD meta-analysis
n = 19 trials provided data (n = 3990 patients)
Change in MLHFQ score at the 12-month follow-up
(6 trials = 626 patients)
• ΔVO2peak direct – 3 trials (252 patients)
• Δ6 MWT – 4 trials (362 patients)
• ΔVO2peak direct and indirect – 6 trials (580 patients)
All-cause mortality
(17 trials = 3782 patients)
• ΔVO2peak direct – 6 trials (2112 patients)
• Δ6 MWT – 6 trials (2154 patients)
• ΔVO2peak direct and indirect – 10 trials (2656 patients)
All-cause hospitalisation
(11 trials = 3190 patients)
• ΔVO2peak direct – 4 trials (1980 patients)
• Δ6 MWT – 5 trials (2078 patients)
• ΔVO2peak direct and indirect – 7 trials (2448 patients)
Change in exercise capacity measurements at 6-month follow-up
ΔVO2peak direct – 6 trials (2112 patients)
Δ6 MWT – 6 trials (2154 patients)
ΔVO2peak direct and indirect – 10 trials (2656 patients)
Change in HRQol (SMD) at the 12-month follow-up
(8 trials = 2643 patients)
• ΔVO2peak direct and indirect – 4 trials (1949 patients)
• Δ6 MWT – 6 trials (2108 patients)
• ΔVO2peak direct and indirect – 8 trials (2476 patients)
FIGURE 12 The PRISMA flow diagram summarising the selection of studies for the ExTraMATCH II surrogate analyses. Δ6MWT, change in 6-minute walk test; ΔVO2peak,
change in VO2peak.
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TABLE 19 Baseline characteristics of patients in surrogate analyses
Baseline variable ExCR group (n= 1345) Control group (n= 1311) All patients (n= 2656)
Age (years), mean (SD) 61.2 (13.0) 61.6 (13.4) 61.39 (13.19)
Gender (male), n (%) 970 (72.1) 973 (74.2) 1943 (73.2)
Baseline ejection fraction, mean (SD) 26.0 (7.9) 26.2 (7.6) 26.1 (7.8)
NYHA class, n (%)
Class I 13 (1) 27 (2) 27 (2)
Class II 834 (62) 861 (64) 848 (63)
Class III 485 (36) 444 (33) 457 (34)
Class IV 13 (1) 13 (1) 13 (1)
Aetiology (ischaemic), n (%) 713 (53) 708 (54) 1421 (54)
Ethnicity (white), n (%) 914 (70) 908 (71) 1822 (70)
VO2peak (ml/kg/minute), mean (SD) 15.1 (4.6) 15.2 (4.8) 15.1 (4.7)
6MWT (m), mean (SD) 368 (108) 366 (110) 367 (109)
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TABLE 20 Characteristics of included studies and interventions in surrogate analyses
Study characteristic n (%), unless otherwise stated
Publication year
2000–9 8 (80)
2010–12 2 (20)
Main study location
Europe 6 (60)
North Americaa 4 (40)
Study centre
Single 7 (70)
Multiple 3 (30)
Sample size
0–99 5 (50)
100–999 4 (40)
≥ 1000 1 (10)
Duration of latest follow-up (weeks), median (range) 10.5 (6–30)
Intervention characteristic
Type of exercise
Aerobic exercise only 6 (60)
Aerobic plus resistance training 4 (40)
Dose of intervention
Duration of intervention (weeks), median (range) 24 (4–120)
Frequency (sessions/week), median (range) 2.75 (2.5–6.5)
Length of exercise session (minutes), median (range) 30 (15–60)
Exercise intensity (range) 40–70% VO2peak
11–15 Borg rating
Setting
Centre based 3 (30)
Home based 2 (20)
Both home and centre based 5 (50)
Borg, Borg Scale of Perceived Exertion.
a HF-ACTION study19 was categorised as North America, but was also delivered to a small number of patients in France.
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TABLE 21 Change in exercise capacity and final patient-relevant outcomes for each included study
Study (year)
ΔVO2peak direct
(ml/kg/minute),
mean difference
(95% CI)
Δ6MWT (m), mean
difference (95% CI)
ΔVO2peak direct
and indirect
(ml/kg/minute),
mean difference
(95% CI)
ΔMLHFQ, mean score
(points) difference
(95% CI)
ΔHRQoL any
validated measure,
mean difference
(95% CI)
All-cause mortality,
HR (95% CI)
All-cause hospital
admission,
HR (95% CI)
Dracup et al.
(2007)58
0.04 (–1.26 to 1.34) 5.19 (–28.39 to 38.78) 0.15 (–0.91 to 1.21) –2.19 (–9.09 to 4.70) –0.15 (–0.44 to 0.15) 1.16 (0.51 to 2.64) 1.31 (0.84 to 2.05
Hambrecht et al.
(2000)51
–2.16 (–4.43 to 0.10) –2.16 (–4.43 to 0.10) 0.93 (0.13 to 6.65) 0.97 (0.14 to 6.88)
HF-ACTION
(2009)19
0.47 (0.24 to 0.71) 18.14 (11.60 to 24.68) 0.43 (0.20 to 0.66) –0.10 (–0.17 to –0.04) 0.92 (0.75 to 1.13) 0.93 (0.83 to 1.03)
Jolly et al.
(2009)61
0.57 (–0.15 to 1.29) 1.35 (–4.02 to 6.71) 0.07 (–0.16 to 0.30) 1.62 (0.45 to 5.78) 0.72 (0.36 to 1.42)
Mueller et al.
(2007)62
4.47 (2.35 to 6.60) 4.48 (2.35 to 6.60) 0.78 (0.33 to 1.85)
Nilsson et al.
(2008)63
77.22 (47.58 to 106.87) 1.78 (1.09 to 2.46) –6.78 (–13.05 to –0.50) –0.30 (–0.57 to –0.02)
Passino et al.
(2006)67
1.57 (0.66 to 2.49) 1.57 (0.66 to 2.49) –23.41 (–28.87 to –17.94) –0.82 (–1.01 to –0.63) 0.48 (0.23 to 0.97)
Witham et al.
(2005)64
5.18 (–17.41 to 27.76) 0.12 (–0.40 to 0.64) 0.04 (–0.40 to 0.49) 0.29 (0.03 to 2.84) 1.03 (0.41 to 2.60)
Witham et al.
(2012)65
–2.03 (–26.14 to 22.08) –0.05 (–0.60 to 0.51) 0.86 (–3.13 to 4.84) 0.04 (–0.16 to 0.24) 2.09 (0.19 to 23.03) 0.94 (0.39 to 2.28)
Yeh et al.
(2011)66
–0.02 (–1.02 to 0.98) 1.25 (–24.71 to 27.20) –0.17 (–1.16 to 0.82) –3.09 (–9.31 to 3.14) –0.16 (–0.43 to 0.12) 0.57 (0.14 to 2.38)
Pooled results 0.69 (–0.24 to 1.62);
p = 0.145, I2 = 80.4%
16.69 (–1.08 to 34.36);
p = 0.066, I2 = 76.5%
0.61 (0.10 to 1.11);
p = 0.019, I2 = 80.3%
–5.53 (–13.27 to 2.21);
p = 0.162, I2 = 91.5%
–0.18 (–0.39 to 0.02);
p = 0.084, I2 = 87.9%
0.83 (0.67 to 1.04);
p = 0.107, I2 = 25.7%
0.90 (0.76 to 1.06);
p= 0.210, I2 = 12.4%
Δ6MWT, change in 6MWT; ΔHRQoL, change in HRQoL score; ΔMLHFQ, change in MLHFQ score; ΔVO2peak: change in VO2peak.
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TABLE 22 Assessment of quality of included studies in surrogate analyses using TESTEX scale
Study (year)
Eligibility
criteria
specified
Randomisation
specified
Allocation
concealed
Groups
similar at
baseline
Blinding of
assessors
Outcome
measures in
> 85%of
participantsa
Intention-
to-treat
analysisb
Between-
group
statistical
comparisons
reported
Point
measures and
measures of
variability
reported
Activity
monitoring
in control
group
Relative
Exercise
intensity
reviewed
Exercise
volume
and
energy
expended
Overall
TESTEX
score
(maximum
score of 15)
Dracup et al. (2007)58 1 0 0 1 0 3 1 2 1 1 1 1 10
Hambrecht et al. (2000)51 1 1 0 1 0 3 0 2 1 0 1 1 11
HF-ACTION (2009)19 1 1 1 1 1 3 1 2 1 1 0 1 14
Jolly et al. (2009)61 1 1 1 1 0 2 1 2 1 0 1 1 12
Mueller et al. (2007)62 1 0 0 1 0 2 1 2 1 0 1 1 10
Nilsson et al. (2008)63 1 1 0 1 1 2 1 2 1 0 0 1 11
Passino et al. (2006)67 1 0 0 1 0 2 1 2 1 0 1 1 10
Witham et al. (2005)64 1 1 0 1 1 3 1 2 1 0 1 0 12
Witham et al. (2012)65 1 1 0 1 1 3 1 2 1 0 1 0 12
Yeh et al. (2011)66 1 1 0 1 1 3 1 2 1 1 0 0 12
a Three points possible.
b If intention to treat was not specifically mentioned, but it was noted that no participants withdrew and all were analysed, then 1 point was awarded.
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Meta-analytic regression: R2 and surrogate threshold effect
Regression coefficients of determination (R2) and correlation coefficients (p-value) between the change in
exercise capacity and hospitalisation were poor (R2trial < 50% and p < 0.50). Moderate to good levels of
correlation (R2trial > 50% and p > 0.50) between exercise capacity VO2peak and 6MWT with mortality and
HRQoL were seen (Table 24). The STE for MLHFQ score ranged from an increase of 1.6 to 4.6 ml/kg/minute
for VO2peak. The STE was not estimable for the 6MWT. Negative correlation coefficients indicate that
larger ExCR effects on exercise capacity are associated with larger ExCR effects on mortality and HRQoL.
Figures 13–15 illustrate the results of the meta-regression and STE analyses.
TABLE 23 Criteria to establish change in exercise capacity as a mediator in the relationship between treatment
effect and patient-relevant final outcomes
Criteria
ΔVO2peak direct
(ml/kg/minute) Δ6MWT (m)
ΔVO2peak direct
and indirect
(ml/kg/minute)
Criterion 1
Treatment assignment has a significant
effect on exercise capacity
0.61 (95% CI
–0.89 to 2.11)
14.61 (95% CI
–6.16 to 35.37)
0.58 (95% CI
–0.35 to 1.51)
Criterion 2
Exercise capacity has a significant effect on
ΔMLHFQ score
–1.64 (95% CI
–2.57 to –0.71)
–0.06 (95% CI
–0.08 to –0.03)
–1.80 (95% CI
–2.77 to –0.83)
Exercise capacity has a significant effect on
ΔHRQoL all measures (SD units)
–0.06 (95% CI
–0.08 to –0.04)
–0.002 (95% CI
–0.003 to –0.001)
–0.07 (95% CI
–0.08 to –0.05)
Exercise capacity has a significant effect on
all-cause mortality (HR)
0.88 (95% CI
0.84 to 0.92)
0.997 (95% CI
0.995 to 0.998)
0.88 (95% CI
0.84 to 0.92)
Exercise capacity has a significant effect on
all-cause hospital admission (HR)
0.93 (95% CI
0.91 to 0.96)
0.998 (95% CI
0.997 to 0.999)
0.94 (95% CI
0.92 to 0.96)
Criterion 3
Treatment assignment has a significant effect on patient-relevant final outcomes:
l ΔMLHFQ score: –5.84 points (95% CI –11.96 to 0.77 points)
l ΔHRQoL all outcomes (SD units): –0.22 (95% CI –0.38 to –0.07)
l All-cause mortality HR: 0.85 (95% CI 0.73 to 0.99)
l All-cause hospital admission HR: 0.91 (95% CI 0.83 to 1.00)
Criterion 4a
The effect of treatment assignment on
ΔMLHFQ score is attenuated when the
change in exercise capacity is added to
the model
–8.28 (95% CI
–18.56 to 2.01)
–1.77 (95% CI
–4.76 to 1.23)
–4.70 (95% CI
–10.81 to 1.40)
The effect of treatment assignment on
ΔHRQoL all outcomes is attenuated when
the change in exercise capacity is added to
the model
–0.28 (95% CI
–0.56 to –0.01)
–0.05 (95% CI
–0.12 to 0.01)
–0.17 (95% CI
–0.31 to –0.02)
The effect of treatment assignment on
all-cause mortality HR is attenuated when
the change in exercise capacity is added to
the model
0.99 (95% CI
0.79 to 1.24)
1.00 (95% CI
0.81 to 1.24)
1.01 (95% CI
0.83 to 1.22)
The effect of treatment assignment on
all-cause hospital admission HR is attenuated
when the change exercise capacity is added
to the model
0.93 (95% CI
0.82 to 1.04)
0.97 (95% CI
0.86 to 1.09)
0.95 (95% CI
0.85 to 1.06)
Δ6MWT, change in 6MWT; ΔHRQoL, change in HRQoL; ΔMLHFQ, change in MLHFQ score; ΔVO2peak, change in VO2peak.
a Mediator-adjusted coefficient.
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TABLE 24 Surrogacy metrics for change in exercise capacity and final outcomes
Surrogate metric
ΔVO2peak direct
(ml/kg/minute) Δ6MWT (m)
ΔVO2peak direct and
indirect (ml/kg/minute)
ΔMLHFQ score R2trial = 94% R2trial = 65% R2trial = 54%
p = –0.80 p = –0.90** p = –0.64
STE 2ml/kg/minute STE not estimable STE 3.2 ml/kg/minute
ΔHRQoL all outcomes (SD) R2trial = 81% R2tria = 54% R2trial = 62%
p = –0.60 p = –0.57 p = –0.53
STE 1.6 ml/kg/minute STE not estimable STE 2 ml/kg/minute
All-cause mortality (HR) R2trial = 21% R2trial = 1% R2trial = 7%
p = –0.89** p = –0.20 p = –0.31
STE 4.6 ml/kg/minute STE not estimable STE not estimable
All-cause hospital admission (HR) R2trial = 26% R2trial = 9% R2trial = 14%
p = –0.20 p = –0.03 p = –0.21
STE 1.8 ml/kg/minute STE 38ml/kg/minute STE 1.8 ml/kg/minute
**p < 0.05.
Δ6MWT, change in 6MWT; ΔHRQoL, change in HRQoL; ΔMLHFQ, change in MLHFQ score; ΔVO2peak, change in VO2peak.
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Small-study bias
There was no evidence of significant small-study bias, as shown by the funnel plots (Figure 16) or Egger’s
test p-values, for any of the exercise capacity outcomes (ΔVO2peak direct, p = 0.699; Δ6MWT, p = 0.93;
ΔVO2peak direct and indirect, p = 0.553), or for the four patient-relevant final outcomes (ΔMLHFQ score,
p = 0.607; ΔHRQoL outcomes, p = 0.659; mortality, p = 0.745; hospitalisation, p = 0.733).
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FIGURE 16 Funnel plots for the surrogate analyses. (a) VO2peak; (b) 6MWT; (c) converted exercise capacity score;
(d) HRQoL; (e) MLHFQ score; (f) mortality; and (g) hospitalisation. (continued )
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FIGURE 16 Funnel plots for the surrogate analyses. (a) VO2peak; (b) 6MWT; (c) converted exercise capacity score;
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Chapter 8 Discussion
The ExTraMATCH II project is a meta-analysis of IPD from HF patients recruited to RCTs conductedworldwide, which sought to determine which HF patient subgroups benefit most from ExCR and assess
the suitability of exercise capacity as a surrogate end point.
Summary of findings
Of the 37 eligible trials, 19 contributed data to the IPD meta-analysis: 18 trials (3912 patients) to the clinical
events (mortality and hospitalisation) analysis; 13 trials (3332 patients) to the exercise capacity and HRQoL
analysis; and 10 trials (2656 patients) to the exercise capacity mediational/surrogate end-point analysis.
Patient characteristics at baseline were well balanced between patients in the ExCR and control groups.
The majority of patients were male (74%), had a mean age of 61 years, had experienced HFrEF (mean left
ventricular ejection fraction of 26.9%) and were in NYHA functional class II (59%) or III (38%). Trials from
Europe and North America were published between 1990 and 2012. Sample sizes ranged from 50 to
2130 patients. All trials evaluated an aerobic exercise intervention, which was most commonly delivered in
either an exclusively centre-based setting or a centre-based setting in combination with some home
exercise sessions. The dose of exercise training ranged widely across trials. ExCR was delivered over a
period of 15–90 weeks, with between two and seven sessions per week (median session duration was
between 4 and 120 minutes, including warm-up and cool-down). The intensity of exercise ranged
between 50% and 85% VO2peak. The overall quality of included trials was judged to be moderate to
good, with a median TESTEX score31 of 11 (range 9–14) out of a maximum score of 15.
Compared with no exercise control, ExCR did not have a statistically significant effect on the risk of
mortality and hospitalisation. However, uncertainty around effect estimates precludes drawing definitive
conclusions for these event outcomes. In contrast, ExCR was found to significantly improve both exercise
capacity and HRQoL, the improvement in MLHFQ score being also clinically important (i.e. a mean
reduction of ≥ 5 points).74 We found no consistent differences in ExCR effects across patient subgroups
(i.e. age, sex, ethnicity, NYHA functional class, ischaemic aetiology, ejection fraction and baseline exercise
capacity) on mortality, hospitalisation, exercise capacity or HRQoL. The validation of exercise capacity as a
putative surrogate end point for patient-relevant outcomes (i.e. mortality, hospitalisation and HRQoL) was
limited by access to only a small number of trials that were able to contribute suitable patient-level data.
Although subject to considerable statistical uncertainty, the results provide indicative evidence that
VO2peak and 6MWT may be suitable surrogate end points for the treatment effect of ExCR on final
outcomes in patients with HF.
Comparison to existing evidence
The finding of a lack of consistent evidence for HF patient subgroup effects of ExCR agrees with both
the previous ExTraMATCH18 and Cochrane analyses.10 However, these two previous studies had major
limitations that are likely to have limited their ability to detect subgroup effects. ExTraMATCH18 included
data on 801 HF patients and observed 88 deaths and 300 patients with a composite outcome of death
or hospitalisation and, therefore, lacked statistical power. Using meta-regression analysis, the 2014
Cochrane review10 found no association between trial-level patient characteristics and ExCR. However,
meta-regression analysis is highly prone to study-level confounding (ecological fallacy) and should be
interpreted with great caution.75
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The findings are also consistent with the IPD subgroup analyses from the multicentre HF-ACTION study.19
The HF-ACTION19 investigators reported no significant interaction effect of exercise training intervention on
their composite primary outcome (i.e all-cause mortality or hospitalisation) and subgroups of age (≤ 70 vs.
> 70 years), sex, race (white vs. non-white), HF aetiology (ischaemic vs. non ischaemic), ejection fraction
(≤ 25% vs. > 25%) or NHYA class (II vs. III/IV).19 A post hoc analysis by HF-ACTION19 investigators found a
significant (adjusted p = 0.02) interaction between ExCR and the change in 6MWT with ExCR and ethnicity
(+26 m in black patients vs. +11 m in white patients), consistent with the current study.76
The validation study results of the suitability of exercise as surrogate outcome, albeit uncertain, are broadly
in agreement with this research team’s recent study based on a trial-level meta-analysis.77
Strengths and limitations
The ExTraMATCH II project has a number of strengths. The IPD meta-analysis is the largest to date and
has greater power to detect any differential treatment effect across groups than single trials or aggregate
meta-analysis. We were able to standardise the handling and analysis of time-to-event outcomes and
continuous outcomes across trials. We found no evidence of publication bias. The project was conducted
and reported in accordance with current IPD guidance and the PRISMA IPD statement.21,78
Although systematic reviews and meta-analyses of IPD from randomised trials are recognised as the gold
standard for assessing intervention effects,79 the study has a number of limitations. First, there was a lack
of consistency in how included trials with IPD in the analyses defined and collected the outcomes of interest
(i.e. time to event for death and hospitalisation, exercise capacity and HRQoL). We made considerable
efforts to contact study authors to clarify issues around the definition of outcomes, especially HF-related
mortality and hospitalisations. Although we were able to resolve data issues in many cases, we recognise
that a lack of consistency in outcome definition across included trials may exist, weakening the strength
of these conclusions. Second, we were not able to obtain IPD from all includable trials for all outcomes;
not all investigators for the trials that met the inclusion criteria were able to provide IPD and, of the trials
that did provide IPD, not all collected the outcomes of interest. For example, the large NIH-funded US
multicentre HF-ACTION study19 did not collect HF-specific hospitalisation data,19 thus reducing the statistical
power for this outcome. Third, we did not seek patient-level data on ‘ExCR dose’ (i.e. adherence according
to exercise training duration, frequency and intensity undertaken by an individual patient). Using IPD from
HF-ACTION,19 Keteyian et al.80 found exercise volume (defined as metabolic equivalent of task hours per
week) to be a predictor for the composite outcome of all-cause mortality or hospitalisation (p = 0.03).
Fourth, there were high levels of statistical heterogeneity for both exercise capacity and HRQoL outcomes.
This heterogeneity may well have reflected the variation in ExCR interventions across the included trials.
Fifth, the analysis is based on randomised trials identified by literature searches up to 2013 and, therefore,
did not include IPD from more recent trials that may have met the inclusion criteria of this study.
Finally, in terms of the surrogate validation analysis, a particular limitation was the proportion of included
trials that provided patient-level data on both exercise capacity and patient-relevant outcomes. Of the
19 trials (3990 patients) that met the inclusion criteria, only 10 trials (2656 patients) provided paired data
on exercise capacity and mortality, hospitalisation or HRQoL. This has a number of implications for the
interpretation of the findings. First, the statistical power of the analysis was low, evidenced by the wide CIs
in pooled analysis and, although all outcomes were in direction of benefit of ExCR, none reached a level of
formal statistical significance at the 5% level. Second, and relatedly, we had limited statistical power to
detect an association between changes in exercise capacity and the final patient-related outcomes. Last,
the results are likely to be subject to selection bias and, therefore, may not be representative of all RCT
evidence.
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Relevance to clinical practice
The observed improvements in patient exercise capacity and HRQoL with ExCR participation support the
class I recommendation of current international clinical guidelines that ExCR should be offered to HF
patients.3,13,15 The findings do not endorse limiting ExCR interventions to subgroups of HF patients.
Research recommendations
In spite of the comprehensiveness of this IPD meta-analysis, the findings of this study demonstrate that
further evidence is still required to definitively assess the impact of ExCR on mortality and hospitalisation in
patients with HFrEF; in particular, to increase the power to examine whether or not the effect of ExCR
varies according to patient characteristics. To more reliably quantify the impact of ExCR on clinical
outcomes and examine how these effects may vary across HF patients, there is an urgent need for trial
investigators to more consistently collect, report and share patient-level data in the future.
Two central aspects of future data collection are a consensus on the definition, collection and reporting of
clinical event data, especially hospitalisation, and the capture of data on patient-level adherence to the
amount of exercise training during the ExCR intervention period. More generally, the research community
should continue to implement policies that encourage primary study authors to make their data sets
available, either by depositing in publicly available repositories or by sharing with IPD meta-analysis
collaborations when directly requested.81
Given that the vast majority of IPD in this study was from HFrEF patients, future trials including HFpEF
patients are needed to assess the effectiveness of ExCR and whether or not there are differential effects of
ExCR in this patient group.
Future IPD meta-analyses of RCTs for interventions in HF are needed to confirm the tentative conclusion
that VO2peak and 6MWT may be suitable surrogate end points for the final patient-related outcomes.
Such future IPD meta-analyses also need to consider individual patient adherence to exercise training.
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Appendix 2 Example database search strategy
from the Cochrane 2014 review
MEDLINE(R) Ovid
Date range searched: 1946 to January week 4 2013.
Date searched: January 2013.
Search strategy
1. xp Myocardial Ischemia/
2. myocard$4 adj5 (ischaemi$2 or ischemi$2)).ti,ab.
3. (ischaemi$2 or ischemi$2) adj5 heart).ti,ab.
4. xp Coronary Artery Bypass/
5. oronary.ti,ab.
6. xp Coronary Disease/
7. xp Myocardial Revascularization/
8. Myocardial Infarction/
9. myocard$5 adj5 infarct$5).ti,ab.
10. (heart adj5 infarct$5).ti,ab.
11. exp Angina Pectoris/
12. angina.ti,ab.
13. exp Heart Failure/
14. (heart adj5 failure).ti,ab.
15. (HFNEF or HFPEF or HFREF or ‘HF NEF’ or ‘HF PEF’ or ‘HF REF’).ti,ab.
16. or/1-15
17. exp Heart Diseases/
18. (heart adj5 disease$2).ti,ab.
19. myocard$5.ti,ab.
20. cardiac$2.ti,ab.
21. CABG.ti,ab.
22. PTCA.ti,ab.
23. (stent$4 and (heart or cardiac$4)).ti,ab.
24. Heart Bypass, Left/or exp Heart Bypass, Right/
25. or/17-24
26. *Rehabilitation Centers/
27. exp Exercise Therapy/
28. *Rehabilitation/
29. exp Sports/
30. Physical Exertion/or exertion.ti,ab.
31. exp Exercise/
32. rehabilitat$5.ti,ab.
33. (physical$4 adj5 (fit or fitness or train$5 or therap$5 or activit$5)).ti,ab.
34. (train$5 adj5 (strength$3 or aerobic or exercise$4)).ti,ab.
35. ((exercise$4 or fitness) adj5 (treatment or intervent$4 or programs$2 or therapy)).ti,ab.
36. Patient Education as Topic/
37. (patient$2 adj5 educat$4).ti,ab.
38. ((lifestyle or life-style) adj5 (intervent$5 or program$2 or treatment$2)).ti,ab.
39. *Self Care/
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40. (self adj5 (manage$5 or care or motivate$5)).ti,ab.
41. *Ambulatory Care/
42. exp Psychotherapy/
43. psychotherap$2.ti,ab.
44. (psycholog$5 adj5 intervent$5).ti,ab.
45. relax$6.ti,ab.
46. exp Relaxation Therapy/or exp Mind-Body Therapies/
47. exp Counseling/
48. (counselling or counseling).ti,ab.
49. exp Cognitive Therapy/
50. exp Behavior Therapy/
51. ((behavior$4 or behaviour$4) adj5 (modify or modificat$4 or therap$2 or change)).ti,ab.
52. *Stress, Psychological/
53. (stress adj5 management).ti,ab.
54. (cognitive adj5 therap$2).ti,ab.
55. meditat$4.ti,ab.
56. *Meditation/
57. exp Anxiety/
58. (manage$5 adj5 (anxiety or depress$5)).ti,ab.
59. CBT.ti,ab.
60. hypnotherap$5.ti,ab.
61. (goal adj5 setting).ti,ab.
62. (goal$2 adj5 setting).ti,ab.
63. (psycho-educat$5 or psychoeducat$5).ti,ab.
64. (motivat$5 adj5 (intervention or interv$3)).ti,ab.
65. Psychopathology/
66. psychopathol$4.ti,ab.
67. psychosocial$4.ti,ab.
68. distress$4.ti,ab.
69. exp Health Education/
70. (health adj5 education).ti,ab.
71. (heart adj5 manual).ti,ab.
72. Autogenic Training/
73. autogenic$5.ti,ab.
74. or/26-39
75. or/40-73
76. 16 or 25
77. 74 or 75
78. 76 and 77
79. randomized controlled trial/
80. randomized controlled trial.pt.
81. controlled clinical trial.pt.
82. controlled clinical trial/
83. Random Allocation/
84. Double-Blind Method/
85. single-blind method/
86. (random$ or placebo$).ti,ab.
87. ((singl$3 or doubl$3 or tripl$3 or trebl$3) adj5 (blind$3 or mask$3)).ti,ab.
88. exp Research Design/
89. Clinical Trial.pt.
90. exp clinical trial/
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91. (clinic$3 adj trial$2).ti,ab.
92. or/79-91
93. 78 and 92
94. (Animals not Humans).sh.
95. 93 not 94
96. limit 95 to yr=‘2008 -Current’
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Appendix 3 Identified randomised controlled
trials meeting inclusion criteria
DOI: 10.3310/hta23250 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 25
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Taylor et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
89
First author/
study (year)
Total
patients
(n)a
Trial setting
(single or
multicentre)
NYHA
class
Mean
ejection
fraction
(%)
Mean age
(years) Male (%)
Exercise
typeb
Overall
exercise
duration
(minutes)
Exercise
frequency
(sessions/
week)
Mean
programme
duration
(weeks)
Exercise
settingc
Longest
follow-up
(months)
Cochrane 2014 review
Austin et al. (2005)70 200 Single II/III NR 72 43 Mix 120 2.5 24 Both 60
Belardinelli et al. (1999)50 99 Single II/IV 28 55 89 Aerobic 40 2.5 56 Centre 26
Belardinelli et al. (2012)56 123 Single II/III 37 59 78 Aerobic 40 2.5 56 Centre 120
Davidson et al. (2010)69 105 Single I/II/III/IV NR 72.3 67 Mix 40 1 12 Centre 12
Dracup et al. (2007)58 173 Single II/IV 26 54 72 Mix 28 4 52 Home 12
DANREHAB (2008)57 91 Single I/II/III NR 66 90 Mix 90 3 12 Both 12
Gary et al. (2010)59 65 Single II/III NR 65.8 42 Aerobic 37.5 3 12 Home 6
Giannuzzi et al. (2003)60 90 Multi II/III 25 60.5 88 Aerobic 30 4 24 Both 6
Hambrecht et al. (2000)51 73 Single I/II/III 29 54 100 Aerobic 15 6.5 24 Both 6
HF-ACTION (2009)19 2331 Multi II/III/IV 25 59 72 Aerobic 30 2.5 120 Both 48
Jolly et al. (2009)61 169 Multi I/II/IV NR 66 75 Mix 25 5 48 Home 12
Klecha et al. (2007)71 50 Single II/III 28 61 100 Aerobic 20 3 24 Centre 6
McKelvie et al. (2002)52 181 Multi I/II/III NR 65.5 81 Mix 30 2 36 Both 12
Mueller et al. (2007)62 50 Single NR NR 55 100 Aerobic 120 5 4 Centre 74
Nilsson et al. (2008)63 80 Single II/III 31 70 79 Aerobic 50 2 16 Centre 12
Passino et al. (2006)67 95 Single I/II/III 34 60.5 87 Aerobic 30 3 36 Home 9
Willenheimer (2001)54 54 Single NR 36.5 64 71.5 Aerobic 30 2.5 16 Centre 10
Witham et al. (2005)64 82 Single II/III NR 80.5 55 Mix 20 2.5 24 Both 6
Witham et al. (2012)65 107 Single II/III NR 81 100 Mix 60 2 24 Both 6
Yeh et al. (2011)66 100 Multi I/II/III 29 67.5 64 Aerobic 30 2.5 12 Both 6
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First author/
study (year)
Total
patients
(n)a
Trial setting
(single or
multicentre)
NYHA
class
Mean
ejection
fraction
(%)
Mean age
(years) Male (%)
Exercise
typeb
Overall
exercise
duration
(minutes)
Exercise
frequency
(sessions/
week)
Mean
programme
duration
(weeks)
Exercise
settingc
Longest
follow-up
(months)
ExTraMATCH I (2004)
Dubach et al. (1997);72
Myers (2002)82
51 NR NR NR NR NR NR NR NR NR NR 8.5
Zanelli et al. (1997)55 155 NR NR NR NR NR NR NR NR NR NR 10
Wielenga et al. (1999)53 80 NR NR NR NR NR NR NR NR NR NR 47.3
DANREHAB, DANish Cardiac ReHABilitation trial; NR, not reported.
a Total number of patients randomised.
b ‘Mix’ includes aerobic and resistance training.
c Exercise settings comprise home, centre or both.
Reprinted from International Journal of Cardiology, Vol. 174, Taylor et al.27 Exercise training for chronic heart failure (ExTraMATCH II): protocol for an individual participant data meta-analysis.,
pp. 683–7, © 2014 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved., with permission from Elsevier. www.sciencedirect.com/journal/international-journal-of-cardiology.
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Appendix 4 ExTraMATCH II core data fields
Variable Description
Study-level data
Centre ID Centre name
Randomised control patients (n)
Randomised exercise patients (n)
Patient-level data: descriptive
Patient ID
Date of randomisation dd/mm/yyyy
Allocated treatment 1. Exercise
2. Control
Date of birth dd/mm/yyyy
Gender 1. Male
2. Female
9. Data unavailable
Race 1. White/Caucasian
2. African/African-American
3. Asian
4. Other
9. Data unavailable
Aetiology of HF 1. Ischaemic heart disease
2. Idiopathic dilated cardiomyopathy
3. Other/unknown
9. Data unavailable
Year of HF diagnosis yyyy
NYHA class at entry/baseline 1. NYHA class I
2. NYHA class II
3. NYHA class III
4. NYHA class IV
9. Unknown/unavailable
Ejection fraction at entry/baseline (%)
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Variable Description
Patient level data: outcomes
Method of exercise capacity assessment 1. 6MWT
2. Bicycle ergometer test
3. Treadmill test
4. Other (state)
Exercise capacity score at entry (units)
Follow-up 1 exercise capacity score Follow-up time (months)
Follow-up 2 exercise capacity score Follow-up time (months)
Follow-up 3 exercise capacity score Follow-up time (months)
HRQoL 1. MLHFQ
2. Other measure (state)
HRQoL at entry Total and subscores
Follow-up 1 HRQoL score Total and subscores
Follow-up time (months)
Follow-up 2 HRQoL score Total and subscores
Follow-up time (months)
Follow-up 3 HRQoL score Total and subscores
Follow-up time (months)
Date of death dd/mm/yyyy
Cause of death 1. Acute myocardial infarction
2. Sudden death
3. Heart failure
4. Other cardiac
5. Stroke
6. Other vascular/thromboembolic
7. Non-cardiovascular
8. Unknown
(1–4, cardiac; 1–6, cardiovascular)
Date of first all-cause hospital admission dd/mm/yyyy
1. De novo hospitalisation
2. Rehospitalisation
Date of first HF hospital admission dd/mm/yyyy
1. De novo hospitalisation
2. Rehospitalisation
Number of all-cause hospitalisations
Number of all HF hospitalisations
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Variable Description
Dropout
Date of study discontinuation dd/mm/yyyy
Reason for study discontinuation
Exercise training (applies only to exercise group patients)
Study-level data
Prescribed exercise training
Overall duration — weeks (ranges if appropriate)
Session duration — minutes (range if appropriate)
Frequency of sessions — sessions/week (range if appropriate)
Intensity — % units (range if appropriate)
Setting 1. Centre only
2. Home only
3. Both centre and home (define proportion of sessions at each
location)
4. Other (state)
Patient-level data
Attended first exercise training 1. Yes
2. No
3. Not reported
Are details available at patient level on exercise dose
received?
1. Yes
2. No
dd, date; ID, identification; mm, month; yyyy, year.
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Appendix 5 Prediction of VO2peak in heart failure
from submaximal exercise tests
6-minute walk test
A number of studies have examined the relationship between 6MWT and VO2peak in HF patients and
reported variable levels of association/correlation. Many studies failed to report a prediction equation or
reported a multivariate equation that incorporated clinical parameters not available in the ExTraMATCH II IPD
set. A recent discussion paper on the use of the 6MWT in HF has questioned the reliability of prediction of
VO2peak.42 However, a review in 2010, by Ross et al.,39 of 11 studies in 1083 patients with cardiopulmonary
disease (many with HF) found generally high levels of association of VO2peak and 6MWT (average correlation
coefficient of 0.59). Using a study-level random-effects linear regression approach, the authors derived the
following overall prediction model, with a standard error of estimate of 1.1 ml/kg/minute:
VO2peak (ml/kg/minute) = 4.948 + 0.023 × 6MWT (m). (1)
Incremental shuttle walk test
Keell et al.40 tested the safety and acceptability of the ISWT in patients with chronic HF and examined the
relationship between ISWT performance and VO2peak:
VO2peak (ml/kg/minute) = (0.27 × number of 10-m shuttles) + 7.77. (2)
Similarly, Fowler et al.41 proposed the following formula in patients following coronary artery bypass
surgery:
VO2peak (ml/kg/minute) = 7.81 + ½0.03 × ISWT distance (m). (3)
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